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PHYSICAL INTERACTIONS BETWEEN NEUROPILIN AND VEGFRS, 
INTEGRINS IN REGULATING ENDOTHELIAL CELL FUNCTIONS 
 
The neuropilin (Nrp) family consists of multifunctional cell surface 
receptors with critical roles in a number of different cell and tissue types. A core 
aspect of Nrp function is ligand-dependent cellular adhesion and migration, 
where it controls the multistep process of cellular motility through integration of 
ligand binding, receptor coupling and signaling via the coordinated action of its 
extracellular and intracellular domains. While Nrp regulates cellular adhesion and 
motility in the cardiovascular and nervous systems under physiological 
conditions, the emerging pathological role of Nrp in tumor cell migration and 
metastasis has been identified and provides motivation for continued efforts 
toward developing Nrp inhibitors.  
 
At the molecular level, the role of Nrp in adhesion and migration is intimately 
connected to the control of adhesive interactions and cytoskeletal reorganization. 
The adhesive “interactome” for Nrp draws much attention because of its lack of 
enzymatic activity and inability to transduce signals on its own. It is an active 
area of research and is still expanding dramatically. Nrp has been well defined as 
a co-receptor for vascular endothelial growth factor receptor (VEGFR)/vascular 
endothelial growth factor (VEGF) signaling through enhancing receptor-ligand 
interaction in angiogenesis. Here, we contribute to this concept through 
characterization in more biochemical detail about Nrp-1/VEGF physical 
interactions. VEGF has been shown to compete with Sema3 for binding to Nrp-1 
b1 ligand binding pocket. This competition fine-tunes VEGF-induced 
angiogenesis. Our data provides a molecular mechanism for high affinity 
Sema3F binding to Nrp-1 in the b1 domain. As to the VEGFR-independent 
function, Nrp/integrin association has been demonstrated. The functional 
integration has been shown for Nrp/integrin in angiogenic sprouting. Both 
proteins are highly expressed in endothelial tip cells to mediate endothelial cell 
migration during angiogenesis and knockdown of either one in mice leads to 
embryonic lethality due to similar defects in vascular development. To identify the 
structure and function correlation, we characterized in more detail about Nrp-
1/integrin physical interactions with biochemical and cell-based assays. Through 
an integrated approach of biochemical, molecular and cellular methods, we 
defined the direct physical interactions between Nrp-1 and integrins. We have 
also extended this work to demonstrate the functional importance and 
contribution of the interactions in integrin-mediated cell adhesion on extracellular 
matrix (ECM) in angiogenesis and platelet function during wound healing and 
provide a molecular basis for the integration of Nrps/integrins in cell migration, 
  
  
adhesion to ECM, breast cancer initiation and breast cancer stem cell fate 
determination.  
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CHAPTER ONE Introduction 
Background 
 Neuropilins (Nrps) are essential vertebrate cell surface receptors that 
function to convert extracellular stimuli into directional cellular migration in 
multiple distinct cell types [1-6]. Two physiologically important Nrp ligand families 
include vascular endothelial growth factor (VEGF) and class 3 semaphorins 
(Sema3) [7-9]. Underlying its role in regulating cellular motility and migration is 
the ability of Nrp to integrate multiple physical mechanisms including ligand 
binding, cellular activation, adhesion, and cytoskeletal reorganization. At the 
molecular level, Nrp functions through specific physical interactions that include 
binding to the canonical ligands Sema3 and VEGF [10], other heparin-binding 
growth factors [11], signaling and adhesive cell surface receptors [10, 12-16], 
and components of the extracellular matrix (ECM), like glycosaminoglycans 
(GAGs) [17, 18].  
There are two Nrp genes, Nrp-1 and Nrp-2, which are conserved in all 
vertebrates [8, 19]. Both Nrp homologs share the same domain organization and, 
in humans, are 44% identical at the amino acid level. The Nrps have a large 
extracellular region, a single-pass transmembrane domain (TMD) helix, and a 
short cytoplasmic tail (Figure 1.1). The Nrp extracellular region directly binds to a 
wide array of molecules that are essential for its versatile function in cellular 
motility. The large extracellular region possesses five structural domains, two 
CUB domains (a1a2), two coagulation factor V/VIII homology domains (b1b2) 
and a MAM domain (c). The TMD has been shown to dimerize intrinsically and is 
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thought to be important for assembling active signaling complexes [20, 21]. The 
Nrp intracellular domain binds to Postsynaptic density 95, Disk large, Zona 
occludens-1 (PDZ)-domain containing proteins [22] and is important for 
regulating interactions with other receptors and the cytoskeleton, thus having an 
essential role in cellular migration [23-26]. Nrp-1 and Nrp-2 have their 
overlapping but unique functions. My thesis focuses on the physical couplings of 
Nrp-1 with other molecules during angiogenesis and wound healing.  
Nrp-1-dependent VEGF signaling 
 Nrp-1 is best understood in its role as an essential signaling co-receptor in 
VEGF-dependent angiogenesis, which occurs within the context of a 
ligand/receptor holocomplex, including VEGF, Nrp-1 and the receptor tyrosine 
kinase (VEGFR-2) (Figure 1.2). As a co-receptor, Nrp-1 functions by directly 
binding ligand and regulating VEGFR-2 signaling and cellular activation [10, 27-
30]. Genetic studies have demonstrated the importance of Nrp-1 within the 
VEGF/Nrp-1/VEGFR-2 holocomplex. Knockout of Nrp-1 in mice results in 
embryonic lethality due to widely distributed defects in vascular patterning [31-
33], which is similar to the phenotype of VEGF heterozygous mice [34, 35] and 
VEGFR-2 null mutant mice [36], although reduced in severity. Conversely, 
overexpression of Nrp-1, which also causes embryonic lethality, induces 
hypervascularization within the cardiovascular system [37]. Interestingly, Nrp-1 
knockout mice demonstrated impaired directional endothelial cell migration, but 
not endothelial cell proliferation [38]. Mechanistic evaluation using HUVEC cells 
showed impaired F-actin reorganization and focal adhesion distribution during 
endothelial cell/ECM attachment caused by Nrp-1 knockdown [39]. A number of 
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studies have also described an essential role for Nrp in endothelial tip cell 
function [40] (Figure 1.3). Endothelial tip cells are specialized cells with extended 
filipodia, sitting at the end of endothelial stalk cells, serving as the leading edge 
of vascular sprouts. Nrp-1 is highly expressed in endothelial tip cell filopodia, 
mediating VEGF-stimulated filopodia extension from the tip cells resulting in 
branching [41, 42]. 
Nrp-1-dependent Sema3 signaling 
Nrp-1 was initially discovered in Xenopus and was shown to be involved in 
mediating neuronal wiring through cell-cell adhesion [43, 44]. Nrp-1 function in 
the nervous system is multifaceted and extends beyond their adhesive properties 
to regulation of both axon guidance and cellular migration. Nrp-1 functions as an 
important co-receptor for the Sema3 family isoforms (Sema3A-G) of axon 
guidance molecules, directly physically coupling with plexin receptors to mediate 
signaling and cellular activation [5, 8, 10, 14, 45, 46]. Genetic studies 
demonstrated that Nrp-1 null mice show defects in neuronal axon pathfinding in 
both the central and peripheral nervous system [31, 32, 47].  
Sema3 engagement by Nrp-1 is more complex than VEGF, and involves 
both the Nrp-1 a1 and b1 domains [48, 49]. Current models indicate that the Nrp-
1 a1 domain binds the sema domain of Sema3s, controlling specificity, while the 
Nrp-1 b1 domain binds to Sema3 C-terminal basic domain, controlling high-
affinity binding [49-54]. This model is impacted by the recent discovery that the 
a2 domain of Nrp integrally interacts with b1 and b2 domains forming a stable 
core [55].  Thus, domain deletion experiments, which generally delete a1a2 or 
b1b2 in tandem, may have more complex interpretations. A recently published 
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structure of Sema3A/PlexinA2/Nrp-1 complex has begun to elucidate the 
molecular details of the Sema3 signaling machinery.  This structure revealed that 
the Nrp-1 a1 domain cross-braces the Sema domains of Sema3A and PlexinA2, 
assembling them to form a dimer of heterotrimers critical for the activation of 
signaling [56, 57].  
Nrp-1 as a versatile co-receptor 
 The extracellular b1b2 domains of Nrp-1 serve a central role in specific 
binding and competition for a large number of ligands [1, 47, 58]. For example, 
VEGF and Sema3 C-termini bind to an overlapping binding pocket formed by the 
coagulation-factor loops of the b1 domain of Nrp-1 [1]. Indeed, Nrp-1 functions as 
a versatile co-receptor depending on its ability to integrate multiple extracellular 
cues that can result in either stimulation or inhibition of the cytoskeleton dynamic 
[10, 59, 60]. For example, VEGF stimulates axon outgrowth [61, 62] whereas 
Sema3F blocks endothelial cell migration [63]. Thus, Nrp-1 function allows 
crosstalk between different ligand families in different tissues and provides 
exquisite control of cellular migration [64, 65]. Regulatory mechanisms controlling 
Nrp-1 ligand binding and the coupling of different domains are an active area of 
research. Post-translational modification of Nrp-1 ligands critically regulates their 
Nrp-1 binding and activity. Alternative splicing and proteolytic processing of the 
VEGF family can dramatically alter Nrp-1 binding and ligand activity [66-71]. 
Proteolytic processing of the C-terminal basic domain of Sema3 family members 
by furin critically regulates their binding to the Nrp b1 domain [72, 73] and 
chemotactic activity [65, 74, 75]. The nature and regulation of signaling cross-talk 
involves competitive binding of the two ligands to the b1 domain of Nrp and is 
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dependent on the furin processing of Sema3 [48, 72, 76, 77]. While the binding of 
the two ligands to Nrp appears to be mutually exclusive in most cases, it is 
theoretically possible to support some level of Sema3 binding either to only the 
Nrp a1 domain or, given recent data indicating a bivalent binding mode for the 
Sema3 C-terminal domain with the Nrp b1 domain, partial engagement in the 
absence of processing [78].  
Nrp-1 as an adhesive receptor 
 Nrp-1 was originally identified as a cell adhesion molecule through 
conferring adhesiveness to fibroblasts via heterophilic interaction with a 
protease-sensitive molecule [43, 79]. Nrp’s adhesive function was later mapped 
to the b1b2 coagulation factor domains, which are responsible for the ECM 
component GAG binding [80, 81]. In addition to GAG-dependent adhesion, Nrp-1 
can couple with other cell surface receptors to modulate cellular adhesion.  
Nrp-1 coupling with integrins 
 While first characterized as an adhesive receptor, the role of Nrp-1 in 
direct cellular adhesion is not as well understood as in signaling. Further, the 
adhesive and signaling functions of Nrp-1 are likely coupled. Recent data 
indicate that Nrp-1 coupling with integrins may underlie its role in cellular 
adhesion and integrate adhesive and signaling functions. Specifically, Nrp-1 has 
been demonstrated to modulate integrin-dependent cellular motility to regulate 
VEGF-stimulated endothelial cell migration in angiogenesis [25].  
 Integrins are the best-documented and well-studied transmembrane 
receptors in mediating cell adhesion and play a dominant role in cell migration 
[82, 83]. On the surface of different cell types, integrins stay either in 
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constitutively active state mediating cell adhesion to the basement membrane, or 
in basally inactive status until stimulated by signals from either the extracellular 
or the intracellular side. In the ‘outside-in’ activation process of integrins (Figure 
1.4), ligand (extracellular matrix) binding to integrin induces conformational 
changes starting from the extracellular domains, across the cell membrane, 
finally to unmask the intracellular tail and promotes their linkage to the actin 
cytoskeleton. The linkage between integrins and cytoskeleton in turn affects the 
dynamic coupling of integrins with their extracellular substrates, which 
contributes to cell adhesion and migration [84].  
 Integrin functions have been coupled to aberrant Nrp-1 function under 
pathological conditions. Nrp-1 is highly expressed in pancreatic ductal 
adenocarcinomas where it associates with β1 integrin to promote cellular 
adhesion and invasion [68]. An interaction between Nrp-2 and α6β1 integrin was 
demonstrated to regulate integrin interaction with the cytoskeleton and focal 
adhesion formation on laminin in breast cancer cells [85]. Likewise, Nrp-2 has 
also been demonstrated to bind α5 integrin and mediate tumor cell extravasation, 
vascular adhesion and metastasis [78].  
The function of the Nrp-1 intracellular domain 
 The Nrp-1 intracellular domain was initially considered dispensable for its 
function in angiogenesis. However, it is now understood that the Nrp-1 
intracellular domain functions to couple ligand binding to downstream mediators 
of angiogenesis. Deletion of the intracellular domain leads to impaired 
arteriogenesis and abnormal retinal artery and vein crossover [86, 87]. Moreover, 
the interacting protein for Nrp-1 C-terminus has been identified. The intracellular 
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adaptor protein RGS-GAIP-Interacting Protein C-terminus (GIPC) contains a 
PDZ domain and interacts with the C-terminus of RGS-GAIP. RGS-GAIP belongs 
to the RGS (regulator of G protein signaling) protein family to regulate Gα-linked 
signaling. The PDZ domain is a modular domain in the signaling proteins 
mediating protein-protein interactions, which is critical for the adaptor function of 
GIPC. GIPC functions to physically and functionally bind to the intracellular 
domain of both Nrp-1 [22] and integrin [88], suggesting a direct mechanism for 
Nrp-1-dependent modulation of integrin function through coupling of intracellular 
domains. Indeed, α5β1 integrin, which binds GIPC, was shown to mediate 
endothelial cell spreading on fibronectin via a mechanism dependent on Nrp-1 
intracellular domain and GIPC [89] (Figure 1.3). Similarly, the Nrp-1 intracellular 
domain coupling with GIPC has also been found to be essential for ligand-
specific receptor localization and trafficking. Binding of VEGF to Nrp-1 induces 
VEGF/Nrp-1/VEGFR-2 complex formation, receptor internalization, and recycling 
back to the membrane [90] (Figure 1.3). 
 
Nrp-1 has critical functions in both physiological and pathological context. While 
the fundamental functions of Nrp-1 in cardiovascular and nervous systems have 
been defined, significant questions have to be elucidated. Characterizing the 
nature of Nrp-ligand binding, including binding specificity and affinity to VEGF 
and Sema3, is key to understand signal initiation and transduction in 
physiological context where Nrp-1 serves as the co-receptor and provide key 
information on the mechanism by which Nrp-1 can physically directly coordinate 
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the actions of multiple factors. Further, Nrp-1 has been demonstrated to be a 
promising therapeutic target against tumor initiation and survival. Additionally, the 
pathological role for trans-cellular adhesion between Nrp-1 and integrins in tumor 
metastasis suggests that it is of particular importance to define the ECD-
mediated physical coupling between Nrp-1 and integrins. Complimentary 
biochemical and cellular methods will allow us to further understand the 
molecular basis and functional implications of specific Nrp-1/ligand or integrin 
interactions.  
With the essential role in cellular adhesion and migration, Nrp-1 functions 
to physically and functionally bind to various ligands, receptors and intracellular 
proteins. Nrp-1 is known to integrate the opposing signals of VEGF and Sema3 
through mediating their competitive binding at the C-terminal arginine-binding 
pocket during vascular and neuronal development. Previous studies demonstrate 
that alternative splicing of VEGF gene generates the exon 8-encoded C-terminal 
arginine residue; while the exposure of Sema3 C-terminal arginine requires 
enzymatic proteolysis. Besides the C-terminal arginine, other amino acid 
residues contribute to both VEGF and Sema3 binding to Nrp-1. Crystal structure 
of VEGF C-terminus in complex with Nrp-1 b1b2 domains suggests that both 
exon 7 and exon 8-encoded regions contribute to the intermolecular interface 
formation. However, the specific and distinct engagement of Nrp-1 with the exon 
7 and exon 8-encoded regions are unknown yet. As to Sema3, current 
competitive antagonists mimicking Sema3 C-terminus show limited potency in 
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inhibiting VEGF binding to Nrp-1 when compared to the endogenous Sema3F. 
Thus, a critical nature of Nrp ligand binding needs to be elucidated.  
In light of functions, Sema3 regulates and fine-tunes VEGF/Nrp-1 
mediated angiogenesis through competitively binding to Nrp-1. It is known that 
the essential vascular function of VEGF occurs within the context of a 
ligand/receptor holocomplex, including VEGF, Nrp-1 and VEGFR-2. Nrp-1 is 
involved in all three steps of the angiogenic cascade, including binding of the 
angiogenic stimulus VEGF, regulating cellular activation by VEGFR-2 and 
controlling directional endothelial migration. The role of Nrp-1 in mediating 
endothelial cell migration appears to be independent of VEGFR-2 and potential 
coordinating receptors may exist. There is a good correlation between the 
structure and function of Nrp-1 in that the extracellular domain, especially the 
b1b2 domains are responsible for extracellular ligand binding, followed by signal 
initiation. The cytodomain is small with no intrinsic enzymatic activities, requiring 
other co-receptors to transduce signals across cell membrane. Thus, the 
VEGFR-2 independent activity of Nrp-1 suggests that Nrp-1 may interact with 
other cell surface receptors to transduce signals. Previous studies suggest a 
functional correlation between Nrp-1 and integrin in angiogenic sprouting, 
indicating that integrin may serve as the candidate receptor that mediates the 
VEGFR-2 independent activities of Nrp-1. During angiogenic sprouting, Nrp-1 
and α5β1 integrin are highly expressed in endothelial tip cells to mediate cell 
migration. The intracellular adaptor protein GIPC functions to physically and 
functionally couple Nrp-1 to α5β1 integrin. GIPC coupled intracellular association 
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promotes integrin recycling from the rear to the front of tip cells to release the old 
and form the new contact with provisional ECM during angiogenesis. So GIPC 
mediated intracellular association may underlie their functional integration in 
angiogenic sprouting. While the VEGFR-2 dependent functions of Nrp-1 and the 
contribution of their physical interactions are well studied, how Nrp-1/integrin are 
coupled and the contribution of their physical interactions are the focus of my 






Figure 1.1 Nrp structure. Nrps contain a large, modular extracellular region that 
facilitates binding to multiple ligand families in both a competitive and non-
competitive fashion. Ligand binding is coupled to intracellular signaling through 
PDZ-domain-containing adaptor proteins that bind the SEA motif of the Nrp 









Figure 1.2 Side view of VEGF/VEGFR-2/Nrp-1 complex in angiogenesis. 
Nrp-1 is an essential component of the VEGFR-2/VEGF signaling complex with 
one VEGF dimeric molecule, two VEGFR-2 monomer molecules and two Nrp-1 
monomer molecules forming a hetero-hexameric complex [91]. VEGF is reported 
to bind to Ig domain 2 and 3 of VEGFR-2 as well as Nrp-1 b1 domain. VEGF 
binding induces the dimerization of both VEGFR-2 and Nrp-1, which in turn 
stabilize VEGF/VEGFR-2 complex. The cartoon structure models were 
regenerated based on the atomic coordinates and structure factors deposited in 


























Figure 1.3 Nrp critically modulates endothelial tip cell function. Nrp is highly 
expressed in endothelial tip cells where it promotes branching and directional 
migration in response to VEGF. In tip cells Nrp serves several essential functions 
including ligand binding, holocomplex formation, integrin coupling, and recycling 






Figure 1.4 Outside–in signaling pathway that can initiate integrin activation. 
Extracellular matrix binding to integrin induces conformational changes that 
activate integrin and increase ligand binding affinity, meanwhile, modifying 
protein interacting sites within the cytodomains and enhancing signal 
transduction, including focal adhesion formation and cytoskeleton reorganization. 
Ligand binding results in integrin clustering, which in turn activates downstream 
signaling pathways and enhance ligand binding strength.  
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CHAPTER TWO Material and methods 
Material and Methods for Nrp-1/integrin interactions 
Protein production and purification 
 Alkaline phosphatase (AP) fused rat Nrp-1 extracellular domain (ECD) 
(residues 24-814), and subdomains a1a2 (residues 24-267), b1b2 (residues 274-
585) and c (residues 594-814) domain in pAPtag-5 (GenHunter, Nashville, TN) 
were produced from Chinese Hamster Ovary (CHO)-S (Invitrogen). Conditioned 
media were purified with heparin affinity chromatography using a 5ml HiTrap 
heparin HP column (GE Healthcare, Piscataway, NJ) for AP tagged Nrp-1 ECD 
and b1b2 or anion exchange chromatography for AP tagged Nrp-1 a1a2 and c.  
 Human Nrp-1 b1b2 (residues 274-585) protein fused with His-tag was 
expressed in Escherichia coli (E.coli) strain Rosetta-gami-2 (Novagen, Madison, 
WI) in pET28a (Novagen) vector. Cells were grown in Terrific-Broth at 37˚C with 
shaking to an OD600 = 1.5 and after incubation at 4˚C for 15 min, cells were 
induced with 1mM isopropyl β-D-thiogalactoside (IPTG). Cells were then grown 
at 16˚C for 16 h and harvested, lysed and centrifuged to get protein supernatant 
which were then purified over His-Select nickel affinity resin (Sigma-Aldrich, St. 
Louis, MO) in 20mM Tris, 200mM NaCl (pH 8.0) buffer with an imidazole gradient 
from 15-300mM followed by heparin affinity chromatography using a 5ml HiTrap 
HP column (GE Healthcare, Piscataway, NJ) in Tris buffered saline with a 
concentration gradient of 300-600 mM NaCl.  
 VEGF-A165 was expressed in E.coli and purified according to previous 
report [35]. Briefly, expressed VEGF-A165 protein was retained in the inclusion 
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body as insoluble protein in E.coli. Inclusion body isolated and homogenized in 
20mM Tris pH 8.0, 100mM NaCl, 0.5% Triton X100 through a homogenizer 
(Kontes Glass Co, Vineland, NJ). The homogenate was centrifuged at 12,000 
rpm for 15 min and then the pellet was then repeated to do resuspension, 
homogenization and centrifugation with the above buffer followed by 20mM Tris 
pH 8.0, 1M Urea buffer. The pellet containing mainly VEGF-A165 was then 
homogenized in 20mM Tris pH 8.0, 8M Urea, 20mM dithiothreitol (DTT) to 
completely reduce the incorrectly folded disulfide bonds. VEGF-A165 should be 
predominantly in the supernatant which was then dialyzed for 24 hours against 
20mM Tris pH 8.4, 400mM NaCl, 1mM Cysteine. The refolded VEGF-A165 protein 
was purified by heparin agarose affinity column (GE Healthcare, Piscataway, 
NJ).  
 α5β1 integrin ECD (Integrin alpha5-AHCys and beta1-tev-BHCy were gifts 
from Timothy Springer Addgen plasmid #27313 and 27314 [92]) was produced 
via large – scale transient co – transfection in CHO-S cells. Heterodimeric α5β1 
ECD was purified from conditioned media by sequential immobilized metal 
affinity chromatography (IMAC) (His-Select, Sigma, St.Louis, MO), anion 
exchange chromatography (5 ml HiTrap Q HP column, GE Healthcare, 
Piscataway, NJ) and size exclusion (HiLoad 16/60 Superdex200, GE Healthcare, 
Piscataway, NJ), producing purified disulfide-linked α5β1 heterodimer.  
 Rat Nrp-1 ECD (residues 21-854) protein was produced via large-scale 
transient transfection in insect Spodoptera frugiperda Sf9 cells (Invitrogen, San 
Diego, CA) using the Baculovirus system. cDNA template of each protein was 
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amplified by PCR and the PCR product was subcloned into the pFASTBAC 
vector (Invitrogen, San Diego, CA) using BamHI and EcoRI restriction sites. The 
resulting construct contains the complete open reading frame of the residues 21 
to 854 fused to the N terminus of the protein. Sf9 cells were cultured in Sf-900 II 
SFM media (Life technology, Grand Island, NY) supplemented with 0.5% 
Penicillin/Streptomycin (Pen/Strep), infected with baculovirus construct 
expressing rat Nrp-1 ECD and processed for expression of recombinant Nrp-1 
ECD according to the manufacturer’s instructions. The protein was secreted into 
the media. For the purification of recombinant Nrp-1 ECD, cleared supernatant 
was loaded sequentially onto IMAC (His-Select, St. Louis, MO) followed by a 5ml 
HiTrap HP column (GE Healthcare, Piscataway, NJ) for heparin affinity 
chromatography.  
Plate binding assay 
 Microplate-based solid-phase protein-protein binding assays were 
performed according to established protocols [72]. Briefly, purified recombinant 
α5β1 ECD (above) or αIIbβ3 ECD (R&D systems, Minneapolis, MN) were 
absorbed to high bind 96-well plates (Corning, 9018) as previously described 
[93]. AP - tagged Nrp-1 constructs with matched AP activity were incubated with 
affinity plates for 1 hour at 25˚C in the presence or absence of 1mM Mn2+ for 
α5β1 and 50µM Mn2+ for αIIbβ3 integrin, an integrin activator [94, 95]. Plates 
were then washed three times with phosphate buffered saline, 0.1% Tween-20, 
pH 7.4 (PBS-T) using an EL404 plate washer (BioTek, Winooski, VT) and 
incubated for an additional 5 min in PBS-T and then aspirated. Retained protein 
was then quantified through addition of 100µl AP Assay Reagent A [96]. The 
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reaction was stopped by adding 100µl 0.5N NaOH and quantified by OD405 using 
SpectraMax M5 instrument (Molecular Devices, Sunnyvale, CA). Retained AP-
activity binding to BSA blocked wells was used as a negative control.  
 To detect the effect of soluble mediators on the interaction between Nrp1 
and α5β1 or αIIbβ3, soluble Nrp1 b1b2, fibronectin (Millipore FC010, Temecula, 
CA), VEGF-A165, fibrinogen (Enzyme Research Laboratories, South Bend, IN), 
the integrin binding sequence RGDS peptide (Tocris Bioscience, UK) or the Nrp-
1 inhibitor ATWLPPR (Lifetein, South Plainfield, NJ) were pre-incubated with 
either AP - Nrp-1 ECD in solution or α5β1/αIIbβ3 affinity plate and the binding 
assays were performed as above. Data were fit using Prism (Graphpad Software, 
La Jolla, CA).   
Cellular assays 
CHO cells – CHO cells were kindly provided by Dr. Zhenyu Li (University of 
Kentucky, Lexington, KY) and Dr. A.F. Horwitz (University of Virginia, 
Charlottesville, VA) and were grown in α-MEM (Gibco, Grand Island, NY) 
supplemented with 10% fetal bovine serum (FBS) (Gibco, Grand Island, NY) and 
1% Pen/Strep (Gibco, Grand Island, NY).  
Mice – The β3-knockout mice [97] on a mixed background of C57BL/6J and 
B129 and corresponding wild-type littermate control were used for platelet 
adhesion; C57BL/6J wild-type mice were used for platelet aggregation. These 
mice were a generous gift from Dr. S.W. Whiteheart (University of Kentucky, 
Lexington, KY).  
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Cellular adhesion of CHO cells 
 Parental CHO-B2 cells that do not express measurable integrin α subunits 
or those that stably express α5β1 or CHO cells stably over-express αIIbβ3 
integrin were grown and utilized as previously reported [98] [99] [100]. Cells were 
detached with PBS, 0.53mM EDTA, pH 7.4, and labeled with 7µM Calcein-AM 
(BD Bioscience 354216, Bedford, MA) at 37˚C for 30 mins. Cells were then 
resuspended in adhesion media (α-MEM media supplemented with 1% BSA and 
20mM Hepes, pH 7.4 buffer) for α5β1 or Tyrodes’ buffer, pH 7.4 (10mM HEPES 
pH 7.4, 137mM NaCl, 2.68mM KCl, 12mM NaHCO3, 0.417mM NaH2PO4, 5.6mM 
D-(+)-Glucose) with 0.35% fatty acid-free bovine serum albumin (BSA; US 
Biological, Swampscott, MA) for αIIbβ3.  
 For α5β1/fibronectin – binding experiments, 250ng of fibronectin per well 
was absorbed on a polysorp microwell 96-well plate (Nunc 437112). For αIIbβ3-
binding experiment, 250ng of Nrp-1 ECD or fibrinogen (Enzyme Research 
Laboratories, South Bend, IN) per well as absorbed on a polysorp microwell 96-
well plate (Nunc 437112). Soluble Nrp-1 b1b2 or RGDS peptide (Tocris 
Bioscience, UK) were pre-incubated in the affinity plate for 15 mins at 37˚C. For 
co-transfection, full length human Nrp-1 was transfected into CHO-B2 or α5 
expressing cells at 80% confluent with 2µg DNA and 12µl Polyethylenimine (PEI) 
per 2ml growth medium α-MEM (Invitrogen, Grand Island, NY) supplemented 
with 1% BSA (Fisher Scientific, Fair Lawn, NJ). Cells were labeled and used for 
adhesion assay 2 day post-transfection. 20µg/ml of the anti-β3 mAb 7E3 [100] or 
disintegrin peptide Echistatin (Tocris Bioscience, UK) were pre-incubated with 
CHO cells for 15 mins at 37˚C.  
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 Calcein-labeled CHO cells were incubated for 2 hours in the affinity plate 
at 37˚C without shaking. Non-adherent cells were removed by washing with 
adhesion media (above). Bound cells were quantified using fluorescence 
(Excitation/emission = 494/517nm, SpectraMax Gemini XPS, Molecular Devices, 
Sunnyvale, CA). The numbers of adherent cells binding to empty wells were 
used for background subtraction and BSA-coated wells as the negative control. 
Fluorescence was converted to the total numbers of adherent cells using a 
standard curve. For αIIbβ3-binding experiment, the subtraction of the total 
numbers of adherent CHO parental cells by that of the CHO-αIIbβ3 cells was 
reported to demonstrate the adherent cells in each condition.  
Platelets preparation and adhesion 
 Human platelets were isolated from platelet-rich plasma (PRP) ordered 
from the Kentucky Blood Center (University of Kentucky).  
 Mouse blood was collected from mice euthanatized by CO2 inhalation and 
mixed with sodium citrate of a final concentration 0.38%.  
 The anti-coagulant blood was mixed with an equal volume of Tyrodes’ 
buffer, pH 6.5 (20mM Hepes pH 6.5, 128mM NaCl, 2.8mM KCl, 12mM NaHCO3, 
0.4mM NaH2PO4, 5mM Glucose, 1mM MgCl2) and centrifuged at 250 X g for 10 
min to get platelet-rich plasma (PRP). 10ng/ml prostaglandin I2 (PGI2) (Sigma) to 
PRP for 5 min and then centrifuged at 500 X g for 15 mins. The platelet pellet 
was then resuspended in Tyrodes’ buffer, pH 6.5, incubated with 0.2 U/ml 
apyrase (Sigma, St. Louis, MO), 10ng/ml PGI2 and 1mM EGTA for 5 min, 
followed by centrifugation at 500 X g for 10 min. The platelet pellet was then 
resuspended in Tyrodes’ buffer pH 7.4 in the presence of 0.02 U/ml apyrase 
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(Sigma, St. Louis, MO) and 10ng/ml PGI2. 7µM Calcein-AM (BD Biosciences 
354216, Bedford, MA) alone or together with 10µl/ml Pluronic F-127, 20% w/v in 
DMSO (Invitrogen, Eugene, OR) was incubated with human or mouse platelets 
respectively at 37˚C with gentle shaking for 30 mins, centrifuged at 500 Xg for 10 
min. The pellet was resuspended in Tyrode’s buffer pH 7.4 in the presence of 
0.02U/ml apyrase at a final concentration of 4 X 108 and 2 X 108 platelets/ml for 
human and mouse platelets respectively. Platelets were incubated with affinity 
plates at 37˚C for 1 hour, washed, and quantified by fluorescence as above.  
Platelet aggregation 
 Mouse platelets (4 X 108/ml) were prepared as described above and 
recalcified with 1mM CaCl2. Platelet suspensions were placed into siliconized 
cuvettes, and aggregation monitored in response to activation. The above steps 
were followed by adding the agonist 20µM ADP (Chrono-Log, Havertown, PA), 
10µM human Nrp-1 b1b2, 10µM refolded VEGF-A165, and 10nM fibrinogen. 
Aggregation was measured as the percent change of light transmission using a 
model 460VS Lumi-Dual-aggregometer (Chrono-Log, Havertown, PA).  
Material and methods for Nrp-1/Sema3F, VEGF-A and VEGFR interactions 
Cell based inhibition assay 
 Porcine aortic endothelial (PAE) cells stably overexpressing Nrp-1 and 
VEGFR-2 were used to detect the potency of C-furSema and C-furSemaHet to 
inhibit VEGF-A induced VEGFR-2 phosphorylation and endothelial cell activation 
[101]. PAE cells were grown to 80% confluence in F12 medium (Invitrogen, 
Grand Island, NY) supplemented with 10% fetal bovine serum (FBS) 
(Invitrongen) as well as 1% Pen/Strep in six-well cell culture plates. Before 
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VEGF-A stimulation, cells were serum-starved for 16 h in Endothelial cell basal 
growth medium – 2 (EBM-2) (Lonza, Walkersville, MD) and then pre-incubated 
with 10µM C-furSema in EBM-2 for 90 min at 37˚C. Immediately, cells were 
stimulated with 100ng/ml VEGF-A (R&D Systems, Minneapolis, MN) for 3 min. 
Cells were then lysed in RIPA buffer supplemented with protease inhibitor and 
phosphatase (Roche). Cell lysates were then applied to SDS-PAGE and then 
transferred to a nitrocellulose membrane using iBlot Gel Transfer Stacks (Novex, 
Israel), probed with 55B11 and 19A10 antibodies (Cell Signaling, Danvers, MA) 
to detect the total and phosphorylated VEGFR-2 respectively at a 1:1000 dilution 
followed by a goat anti-rabbit horseradish peroxidase (HRP) – conjugated 
secondary antibody at 1:20,000 dilution (sc-2301, Santa Cruz). Experiments 
were performed three independent times.  
Protein production and purification  
Protein production in Spodoptera frugiperda Sf9 cells 
1. Cloning into pFASTBAC donor plasmids 
Clone your gene of interest into a pFASTBAC donor plasmid, the 
sequence of which is shown in Figure 2.1. I made the following constructs: 
human VEGFR-1 D1-7 (27aa-758aa) and D1-4 (27aa-431aa); human VEGFR-2 
D1-7 (20aa-764aa), D1-4 (20aa-424aa) and D3/4 (220aa-424aa); human 
VEGFR-3 D1-7 (21aa-776aa), D1-4 (21aa-425aa) and D3/4 (226aa-425aa) and 
mouse VEGF-A164 (27aa-190aa). I ligated the BamHI and EcoRI digested 
pFASTBAC vector and the insert fragments under the appropriate conditions. 
Ligated plasmids were transformed into DH5α competent cells and the 
transformation was plated onto LB agar plates with 100µg/ml ampicillin for 
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plasmid selection and incubated at 37˚C overnight. Grown colonies were 
screened and plasmid DNA was prepared to verify the correct insertion of the 
gene of interest through DNA sequencing.  
2. DNA transformation into DH10BAC and transposition into Bacmid plasmid 
1) Prepare Luria Agar plates for DH10BAC transformation 
For 400ml solution, 10g LB powder and 6g agar powder were added to 400ml 
ddH2O followed by autoclave. 2ml 10mg/ml Kanamycin, 0.4ml 7mg/ml 
Gentamycin and 2ml 2mg/ml Tetracyclin were added to make final concentration 
of 50µg/ml Kanamycin, 7µg/ml Gentamycin and 10µg/ml Tetracyclin.  
2) DH10BAC competent cell transformation 
10µl DH10BAC cells were mixed with approximately 500ng recombinant 
pFASTBAC vector inserted with your gene of interest and incubated on ice for 30 
min. The mixture is then heat shocked in 42˚C water bath for 45 secs and 
immediately chilled on ice for 2 min. 100µl S.O.C medium was then added to the 
mixture which was then placed at 37˚C with medium agitation for 4 hours. The 
cells were diluted with S.O.C medium by 100 times and 100µl of the dilution was 
placed on the luria agar plates and incubated at 37˚C for 48 hours until the blue 
and white colonies can be discernible.  
3) Preparation of recombinant Bacmid DNA 
Transposition of foreign genes into bacmid vector disrupts the lacZ gene, leading 
to the identification of colonies containing recombinant bacmids that are white. 
White colonies were selected to isolate recombinant bacmid DNA using the 
following procedure: (1) Inoculating a single white colony into 5ml LB medium 
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supplemented with 50µg/ml Kanamycin, 7µg/ml Gentamicin and 10µg/ml 
Tetracycline. Grow at 37˚C with shaking at 250rpm overnight. (2) Aliquot 
bacterial solution into 1.5ml of culture in centrifuge tube and centrifuge at 14,000 
X g for 1 min. (3) Vacuum aspirating the supernatant and resuspending the cell 
pellet by gentle vortexing in 300µl of Solution I (15mM Tris-HCl pH 8.0, 10mM 
EDTA, 100µg/ml RNase A). Add 300µl of Solution II (0.2N NaOH, 1% SDS) to 
precipitate DNA and gently mix those two solutions. Incubate at room 
temperature for 5 mins. (4) Add 300µl 3M potassium acetate pH 5.5 to neutralize 
NaOH and mix gently. Place the samples on ice for 15 min. (5) Separate the 
precipitate from the solution through centrifugation for 15 min at 14,000 X g and 
mix the supernatant with 0.8ml isopropanol. Place the sample on ice for 15 min. 
(6) Precipitate DNA through centrifugation at 14,000 X g for 20 min at room 
temperature. (7) Wash the DNA pellet with 500µl 70% ethanol for three times. 
Finally remove the ethanol as much as possible and air dry the pellet. Dissolve 
the DNA in sterilized distilled water. Quantify the DNA and verify DNA sequence 
through PCR using the M13/pUC Forward Amplification Primer (Forward) / your 
gene-specific anti-sense (reverse) primer pair or the M13/pUC Reverse 
Amplification Primer (Reverse) / your gene-specific forward primer pair. Insertion 
of your gene into the pFASTBAC vectors leads to an increase in the size of the 
PCR product. For the M13 Forward / your gene-specific reverse primer pair, the 
size of the PCR product equals to 1.5 kb + your insertion size; for the M13 
Reverse / your gene-specific forward primer pair, the size of the PCR product 
equals to 0.5 kb + your insertion size.  
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3. Transfection of Sf9 cells with recombinant Bacmid 
 Add 5ml Pen/Strep into 1L Sf-900 II SFM medium (Life technology, Grand 
Island, NY); leave 50ml medium without antibiotics. Seed 0.9 X 106/ml cells in 
6ml medium in 100mm dish and sit in the hood for 1 hour. During cell attachment, 
prepare Solution A and Solution B: 
1) Solution A: 15µl DNA + 300µl medium without Pen/Strep; 
2) Solution B: 18µl Cellfectin (Invitrogen, Carlsbad, CA) + 300µl medium without 
Pen/Strep; 
3) Mix Solution A and Solution B and sit in the hood for 45 min; 
Wash attached cells with 3ml medium without Pen/Strep per dish for two times. 
Add 2.4ml medium without Pen/Strep into each dish and add 0.6ml Solution A + 
Solution B mixture drop by drop into each dish. Mix by inverting the dishes slowly. 
Incubate the cells with DNA mixtures at 27˚C without shaking for 5 h. Remove 
the old medium containing DNA + Cellfectin and add 6ml medium with Pen/Strep 
per dish. Incubate the transfected cells with fresh medium at 27˚C without 
shaking for 3 day in humidity. Collect the supernatant which contains secreted 
proteins as P1. Leave 4ml P1 at 4˚C for storage and amplify 1ml P1 to 9ml 2 X 
106/ml cells with 1:10 ratio and incubate at 27˚C with shaking at 121 rpm for 3 
days. Collect the supernatant which contains secreted proteins as P2 through 
spinning down at 2000 rpm for 5 mins. Do western blot to check protein 
expression in P2, which is probed with anti-His antibody. If there is protein 
expression, continue to the next steps. Amplify P2 to P3 with 1:10 ratio and 
collect the supernatant to do large-scale inoculation with 1:50 ratio using 2 X 
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106/ml cells. Incubate the transfected cells at 27˚C with shaking for 3 days and 
collect the supernatant through centrifugation at 2000 rpm for 10 mins. Add 25ml 
1M Tris pH 8.0 per 1 L supernatant and incubate at 4˚C for at least 30 min to 
adjust the pH to 8.0 for the following protein purification (the fresh Sf9 medium 
has acidic pH). Spin again at 5000 rpm for 30 mins to remove the precipitate. 
Collect and filter the supernatant. Concentrate and buffer exchange (20mM Tris 
pH 8.0, 200mM NaCl, 15mM Imidazole) the supernatant at 4˚C until around 50ml 
in volume.   
Protein purification 
  AP tagged Nrp-1 ECD and subdomains are generated as described 
above.  
 Human VEGFR-2 D1-7 (residues 20-764), subdomains Ig D1-4 (residues 
20-424), Ig D3/4 (residues 220-424), human VEGFR-1 D1-7 (residues 27-758), 
mouse VEGF-A164 (residues 27-190) and rat Nrp-1 ECD (residues 21-854) were 
produced via large-scale transient transfection in Sf9 cells (Invitrogen, San Diego, 
CA). Secreted proteins were purified from conditioned media by sequential IMAC 
(His-Select, Sigma, St.Louis, MO) and size exclusion Superdex 200 (HiLoad 
16/60 Superdex 200, GE Healthcare, Piscataway, NJ) for D1-7 and Superdex 75 
(HiLoad 16/60 Superdex 75, GE Healthcare, Piscataway, NJ) for D1-4 and D3/4.  
Plate binding assay 
 Before doing the real protein-protein binding assay, we did His-tag protein 
ELISA to accurately quantify His-tagged VEGFR ECD and subdomains to make 
sure the equal coating efficiency of different His-tagged proteins. Briefly, prepare 
His-tagged protein affinity plate through loading 100µl/well series concentrations 
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of His-tagged proteins to 96-well high binding plate (Corning 9018) and 
incubating at 37˚C for 1 hour. The non-bound proteins were washed away and 
100µl/well anti-His horseradish peroxidase (HRP) mAb (sc-2301, Santa Cruz 
Biotechnology) diluted 1:100 with pellicon buffer (20mM Tris pH 7.5, 50mM NaCl) 
was added and incubated at RT for 30 min. Then the non-bound mAb was 
washed away. 100µl/well HRP substrate Tetramethylbenzidine (TMB) was added  
to produce a blue byproduct. The color intensity is proportional to HRP activity, 
which is correlated with the coated His-tagged proteins. Finally, 100µl/well 2N 
sulfuric acid (H2SO4) was added to stop the reaction and change the color from 
blue to yellow, which has an absorbance maximum at 450nm. Quantify the color 
intensity by OD450 using SpectraMax M5 instrument (Molecular Devices, 
Sunnyvale, CA). A standard curve (concentration vs. color intensity) is generated 
for each His-tagged protein to compare their coating efficiency. Next, microplate-
based solid-phase protein-protein binding assays were performed according to 
established protocols [72]. Briefly, purified human VEGFR-2 or VEGFR-1 
extracellular domains or subdomains with equal coating efficiency were absorbed 
to high bound 96-well plates (Corning, 9018) as previously described [93]. AP 
tagged Nrp1 ECD alone or together with subdomains of matched AP activity was 
incubated with VEGFR affinity plates for 1 hour at 25˚C. Plates were then 
washed three times with phosphate buffered saline, 0.1% Tween-20, pH 7.4 
(PBS-T) using an EL404 plate washer (BioTek, Winooski, VT) and incubated for 
an additional 5 mins in PBS-T and then aspirated. Retained protein was then 
quantified through addition of 100µl AP Assay Reagent A [96]. The reaction was 
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stopped by adding 100µl 0.5N NaOH and quantified by OD405 using SpectraMax 
M5 instrument. Retained AP activity binding to BSA blocked wells was used as a 
negative control and subtracted to report the final retained AP activity of bound 
Nrp-1.  
 To detect the effect of VEGF-A on the interaction between Nrp-1 and 
VEGFRs, VEGF-A was pre-incubated with VEGFR affinity plates and the binding 
assays were performed as above. Data was fit using Prism (Graphpad Software, 



















Figure 2.1 pFASTBAC vector sequence. pFastBac plasmid DNA sequence is 
shown above, with signal sequence, StrepII tag, His-tag, precission protease 
cleavage site as well as multi-clonal restriction sites for the insertion of your gene 





CHAPTER THREE Direct physical interaction between Nrp-1 and α5β1 
integrin extracellular domains promotes cell adhesion to fibronectin 
Introduction 
Angiogenesis is the formation of new blood vessels from pre-existing 
ones, and is critical in both physiological and pathological contexts [102, 103]. 
The angiogenic cascade is initiated by the binding of pro-angiogenic growth 
factors to receptors expressed on endothelial cells of existing vasculature [104, 
105]. This binding activates a coordinated cascade involving endothelial cell 
activation, proliferation, and directional migration [106-108]. VEGF is one of the 
most potent pro-angiogenic growth factors, and signals via two families of cell 
surface receptors: VEGFR [109-112] and Nrps [1, 47, 58]. The coordinated 
activity of both receptors is required for physiological angiogenesis, with VEGFR 
critical in endothelial cell activation and proliferation [113] and Nrp critical for 
endothelial cell migration and adhesion [114, 115]. Initial work demonstrated that 
Nrp-1 knockdown caused impaired F-actin reorganization and focal adhesion 
distribution during endothelial cell attachment to the extracellular matrix ECM 
[39].  More recently, in vivo data demonstrated that Nrp-1 knockout results in 
embryonic lethality due to defects in endothelial cell migration [38].   
Nrp has a large extracellular domain with organized subdomains termed 
CUB domains (a1a2), coagulation factor V/VIII homology domains (b1b2), MAM 
domain (c); a single transmembrane domain; and a small intracellular tail (Figure 
1.1). The Nrp extracellular domain directly binds to a variety of molecules that are 
critical for the initiation of its versatile functions in cellular motility. Nrp-1 was 
originally identified as a cell adhesion molecule [43, 79], conferring adhesiveness 
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through heterophilic interaction with a protease-sensitive molecule. It was further 
shown that the adhesive functionality of Nrp was in the ligand binding b1b2 
domains, but did not involve canonical signaling receptors in either VEGF or 
semaphorin signaling pathways [80].   
The mechanistic basis for Nrp function in the control of endothelial cell 
directional migration is an active area of research, and involves extracellular 
ligand binding [10, 11], engagement with other cell surface receptors [10], ECM 
components [17, 18], and intracellular signaling proteins. Recently Nrp function 
has been demonstrated to modulate cellular adhesion and migration mediated by 
multiple integrins, in both physiological and pathological settings including 
endothelial cell (EC) adhesion on fibronectin [25], breast cancer cell adhesion to 
laminin [16], breast cancer initiation [116], cancer cell extravasation and 
metastasis [78], pancreatic cancer cell invasion [68] and breast cancer stem cell 
fate determination [117]. In particular, α5β1 has been connected with Nrp 
function in multiple settings, especially serves as a key regulator of angiogenesis 
both physiologically and pathologically [118-121] and tumor cell migration [122, 
123]. α5β1 integrin is the primary receptor for fibronectin, a key component of the 
ECM [124-127]. Moreover, the α5β1 and fibronectin ligand-receptor pair is the 
key pro-angiogenic factor mediating vascular development [128]. Further co-
localization of Nrp-1 with active α5β1 has also been reported in the tumor 
microenvironment, which results in increased fibronectin fibril assembly [129]. 
The intracellular adaptor protein GIPC1 (RGS-GAIP-interacting protein C-
terminus) has been shown to bind to the intracellular domain of both Nrp-1 [22] 
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and α5β1 [88]. Indeed, α5β1 was shown to mediate endothelial cell spreading on 
fibronectin through a mechanism dependent on the Nrp-1 intracellular domain 
and GIPC1 [25]. Furthermore, it was demonstrated that the Nrp-1 intracellular 
domain directly binds and traffics protein components of focal adhesions, 
functioning to promote rapid focal adhesion turnover and cellular migration [130].  
For these reasons, it has been widely thought that GIPC1-mediated bridging of 
intracellular domains was necessary and sufficient to explain the physical and 
functional coupling between Nrp-1 and α5β1. However, recent data 
demonstrated a trans-cellular interaction between Nrp and integrin in tumor cell 
adhesion and transmigration across endothelial cells during pathological 
metastasis [78]. This data opened up the question about physical coupling 
between Nrp and integrin in the extracellular space.   
Here we demonstrated a direct physical interaction between ECD of Nrp-1 
and α5β1 and further mapped the interaction to the ligand binding domains. This 
interaction is enhanced by fibronectin, which is an important component of 
provisional ECM. We further demonstrated that this extracellular ternary 
interaction is a key functional component of Nrp-promoted binding of α5β1 to 
fibronectin in cellular context.  
Results 
Integrin α5β1 and Nrp-1 extracellular domains directly interact 
To test for a direct physical interaction between Nrp-1 and α5β1, direct 
binding of AP-tagged Nrp-1 ECD to immobilized purified α5β1 ECD was 
measured (Figure 3.1). The structures and functions of integrins are divalent 
cation-dependent. In the experiment, divalent cations were applied, either Ca/Mg 
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(-Mn group) or Mn (+Mn group). Ca is essential for the heterodimeric association 
between α5 subunit and β1 subunit and Mg is required for stabilization of the 
metal ion-dependent adhesion site (MIDAS) within the ligand binding pocket and 
coordination of ligand binding. The Nrp-1 ECD was found not to interact with the 
α5β1 ECD in the presence of Ca/Mg. Mn binding artificially switches the 
conformation to a high affinity state of integrin, mimicking but bypassing the 
requirement for inside-out activation signaling pathways [94, 95]. The Nrp-1 ECD 
was found to directly and specifically interact with the α5β1 ECD in an integrin 
activation-dependent manner. 
We next sought to identify the motifs in Nrp-1 ECD responsible for 
interacting with α5β1. The Nrp-1 ECD is a module combination. Based on the 
sequence identity, structure similarity and ligand binding properties as well as 
physiological functions, the Nrp-1 ECD was subdivided into the three domain 
combinations: a1a2, b1b2 and c domains (Figure 3.2A). Nrp-1 a1a2 domains are 
the major binding sites for Sema3s to mediate axon guidance, especially the a1 
domain cross-bracing the sema domain of Sema3 and plexin to form the 
signaling competent complex [57, 131]. C domain is also called MAM domain, 
the abbreviation of meprin, A5 and receptor tyrosine phosphatase mu and kappa 
which three share sequence homology. Nrp-1 c domain participates in the 
oligomerization of Nrp-1 and semaphorin signal transduction [49, 52]. Nrp-1 b1b2 
domains bind to the VEGF family, such as VEGF-A and placental growth factor-2 
(PlGF-2) [10, 58, 81]. Thus, the modular organization of Nrp-1 ECD structure 
represents a well-documented correlation with its pleiotropic physiological 
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functions. The detection of the binding of AP tagged Nrp-1 extracellular 
subdomains to α5β1 affinity plates found that the Nrp-1 ECD binds directly to 
α5β1 ECD using its extracellular b1b2 domains, whereas neither a1a2 domains 
nor c domain alone bound significantly (Figure 3.2A). To confirm this result, 
soluble Nrp-1 b1b2 protein was used as a competitor against the full Nrp-1 ECD 
(Figure 3.2B).  Dose-dependent inhibition was observed with an IC50=230 ± 
33nM. These data demonstrate a direct integrin activation-dependent physical 
interaction between the Nrp-1 b1b2 domains and α5β1 ECD. The b1b2 domains 
have been assigned as the adhesive sites of Nrp-1 in mediating cell adhesion 
[132] and binding to the extracellular matrix components heparin [58] as well as 
glycosaminoglycans (GAGs) [81]. We demonstrated here for the first time that 
b1b2 domains are the binding sites for other adhesive receptors.  
Ligand effect in Nrp-1/α5β1 integrin interaction in the extracellular domains 
Nrp-1 has been shown to promote fibronectin fibril assembly, leading to 
matrix stiffness and tumor metastasis [129]. Nrp-1 has also been shown to 
enhance endothelial cell adhesion specifically to fibronectin, but not to other ECM 
components, like vitronectin, collagen I and laminin I [89]. This promoting effect 
suggests that Nrp-1 may also directly interact with fibronectin. Moreover, α5β1 is 
the major receptor for fibronectin. The specific Nrp-1/α5β1 association and 
α5β1/fibronectin specificity led us to detect the binding ability of Nrp-1 to 
fibronectin. To test the hypothesis, the direct interaction of Nrp-1 ECD and 
fibronectin was measured (Figure 3.3). Indeed, direct physical binding of Nrp1 
ECD to fibronectin was observed (Figure 3.3A). This interaction was inhibited by 
the Nrp-1 ligand competitive inhibitor ATWLPPR (Figure 3.3B), indicating that 
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fibronectin is interacting as a canonical Nrp-1 ligand binding to the b1 ligand-
binding pocket [133]. Nrp-1 has been demonstrated to interact with multiple 
structurally unrelated ligands, like VEGF-A, PlGF-2 and fibroblast growth factor 
(FGF), which all contain the heparin-binding domains [58, 134, 135], indicating 
that heparin binding domains of the above proteins contribute to Nrp-1 binding. 
Indeed, there is a continuous electronegative region on the surface of Nrp-1 b1b2 
domains that serves as heparin mimicking site and binds to the heparin binding 
sites of these proteins [93, 135]. Fibronectin contains two heparin-binding sites. 
VEGF binds to the heparin-II domain of fibronectin [136]. We suggest that these 
heparin-binding domains of fibronectin may serve as the binding sites for Nrp-1. 
In contrast to fibronectin, the interaction between Nrp-1 and α5β1 was not 
affected by this Nrp-1 ligand binding inhibitor (Figure 3.3C), indicating that 
integrin and fibronectin binding sites are located on distinct regions of the Nrp-1 
ECD.  
Because the binding sites on Nrp-1 are distinct, and each binary 
interaction was established, we next tested whether the three components can 
form a functional ternary complex.  The effect of fibronectin in modulating the 
interaction between Nrp-1 and α5β1 was measured (Figure 3.4). Increasing 
concentrations of fibronectin significantly promoted the interaction of Nrp-1 and 
α5β1 ECDs in a dose-dependent manner, indicating cooperative binding of the 
three components in a ternary complex (Figure 3.4). 
Nrp-1 promotes α5β1 integrin mediated cell adhesion to fibronectin 
GIPC-mediated crosslinking of Nrp and integrin intracellular domains had 
previously been demonstrated to allow Nrp-promoted adhesion to ECM in cellular 
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context. Indeed, consistent with literature reports [89], we observed α5β1 
integrin-mediated binding of CHO cells to fibronectin that is significantly 
enhanced upon co-expression of full-length Nrp-1 (Figure 3.5A). To determine 
the specific role of the Nrp-1 ECD, we next tested the ability of Nrp-1 to promote 
cellular adhesion in trans. Addition of Nrp-1 b1b2 resulted in a robust dose-
dependent enhancement of α5β1-expressing CHO cell adhesion to fibronectin 
(Figure 3.5B). In contrast, Nrp-1 does not support adhesion to fibronectin in 
isolation.  Further, the integrin blocking peptide RGDS inhibited Nrp-1 promoted 
binding, demonstrating that cell adhesion is α5β1 integrin dependent. Strikingly, 
the enhancement in fibronectin adhesion observed upon addition of 1µM Nrp-1 
b1b2 was to the same level as co-expression of full length Nrp-1 (Figure 3.5B). 
Thus, in cellular context, ECD-mediated bridging of Nrp-1 and α5β1 can fully 
recapitulate the observed enhancement of ECM-mediated adhesion and the pro-
adhesive activity of Nrp-1 b1b2 domains to ECM requires the presence of α5β1 
integrin.  
Discussion 
 Here we reported that Nrp-1 ECD directly interacts with α5β1 integrin 
ECD. This interaction is mediated by the Nrp-1 b1b2 ligand binding domains and 
is integrin activation-promoted. We further demonstrated that the integrin ligand 
fibronectin promotes the interaction, and that this ECD-mediated interaction is 
critical for Nrp-promoted integrin function in cellular context and provides a 
physical context for important physiological function of Nrp-1 in mediating cell 
adhesion and migration. The ECD-mediated interaction with α5β1 is predicted to 
be critical for directional migration of endothelial cells in angiogenesis and may 
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also provide a context for understanding pathological functions, including tumor 
cell adhesion and migration across endothelial cells [78]. 
We further demonstrated a direct interaction between Nrp and fibronectin, 
with fibronectin binding to the conserved ligand binding sites of Nrp. Mediating 
ECM interactions may be a more general feature of Nrp. Physiologically, Nrp-1 
has been shown to facilitate primary human endothelial cell adhesion to laminin, 
fibronectin and gelatin [39]. Pathologically, Nrp-1 suppression decreased 
pancreatic cancer cell adhesion to fibronectin, laminin and collagen IV [68]. It will 
be interesting to discover the extent of Nrp/ECM interactions, and whether these 
interactions are coupled to or competitive with binding of canonical signaling 
ligands.  
 There are two Nrp genes, Nrp-1 and Nrp-2, which are conserved in all 
vertebrates [8, 19]. Importantly, both have been reported to functionally associate 
with different integrins in cellular context [78, 85, 89]. It has been reported that 
αvβ3 integrin interacts with Nrp-1 in a VEGF-dependent manner that sequesters 
Nrp-1 away from VEGFR-2, thus inhibiting VEGF-induced angiogenesis [137]. 
Nrp-2 has been reported to interact with α6β1 integrin and participate in laminin-
dependent adhesion and specific integrin localization to focal adhesions [85]. 
Moreover, Nrp-2/α6β1 autocrine loop has been reported to contribute to breast 
cancer initiation [116]. However, it was clearly demonstrated that Nrp-2 does not 
interact with α3β1 integrin, which is also a laminin receptor and Nrp-2 cannot 
activate ligand binding function of α3β1 integrin, indicating that selective Nrp 
association contributes to the specific integrin signaling. It will be important to 
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define the binding and specificity of Nrp-1/2 to various integrins at the molecular 
level to understand the contributions of Nrps in physiological and pathological 
cellular functions of integrins.  
 The data presented here demonstrate that ECD-mediated interaction of 
Nrp and integrin has an important physical and functional role. ECD-mediated 
interactions are clearly necessary for trans-interactions involved in tumor cell-
endothelial cell adhesion during metastasis [78]. However, in cis, this interaction 
likely is cooperative with GIPC-mediated bridging of Nrp and integrin intracellular 
domains. Both Nrp-1/Nrp-2 and α5/α6 intracellular domains have been shown to 
bind to GIPC [22, 138]. Intracellular coupling is thought to be critical for 
controlling receptor trafficking and recycling [89, 139, 140]. Integrins in the cell 
membrane are constitutively internalized and recycled back to the plasma 
membrane [141, 142]. 
 Understanding the generality and specificity of Nrp-1/integrin association 
and functions helps to define the contribution of Nrp-1 in the process where 
integrins function as mechanosensors, adhesion molecules, and in signal 
transduction. Since integrins are critical mediators in the pathology of many 
diseases, integrin targeted therapeutics are of great interest in disease treatment 
and prevention. While current therapeutic strategies focus on targeting ligand 
binding, inhibition of receptor coupling represents another mode of action for 
targeting integrin signaling. Indeed, it was recently reported that Nrp-1 inhibition 
enhanced the anti-adhesive effects of β1 integrin-inhibition in carcinoma cells 
[143], suggesting a synergistic role of targeting Nrp-1/α5β1 integrin coupling in 
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antagonizing tumor survival, adhesion and migration. Blockade of Nrp-1/integrin 
coupling may provide synergistic benefit, especially in control of pathological cell 































Figure 3.1 Nrp-1 ECD directly interacts with α5β1 integrin ECD. Nrp-1 directly 









Figure 3.2 Nrp-1 b1b2 domains are the binding sites for α5β1 integrin. A) 
Schematic representation of Nrp-1 extracellular domains. Nrp-1 b1b2 domains 
are necessary and sufficient for the interaction with α5β1 integrin. B) Soluble 







Figure 3.3 Nrp-1 directly binds to fibronectin. A) Purified human plasma 
fibronectin shows significant binding to Nrp-1 compared to BSA control. B) The 
ligand-competitive Nrp-1 inhibitor ATWLPPR inhibits the Nrp-1/fibronectin 
interaction. C) In contrast, ATWLPPR does not affect Nrp-1/α5β1 integrin 
association. Statistical significance was calculated using student t test in which * 















Figure 3.4 Fibronectin enhances Nrp-1/α5β1 integrin interaction. Addition of 
fibronectin results in a dose-dependent enhancement in Nrp-1/α5β1 integrin 









Figure 3.5 Nrp-1 enhances α5β1 mediated cellular adhesion to fibronectin in 
trans. A) α5β1 mediated cell adhesion to fibronectin is enhanced by co-
expression of Nrp-1. B) Addition of Nrp-1 b1b2 to fibronectin affinity plates, 
specifically enhances α5β1 mediated cell adhesion on fibronectin in a dose-
dependent manner (0.001, 0.01, 1µM) to the same extent as co-expression of full 





CHAPTER FOUR The direct physical interaction between αIIbβ3 integrin 
and Nrp-1 in the extracellular domain contributes to platelet physiology 
Introduction 
 In chapter three, our data showed that there is a direct physical interaction 
between Nrp-1 and α5β1 integrin in the extracellular domain, providing the 
molecular mechanism underlying the reported enhanced tumor cell 
transmigration across endothelial cell during pathological metastasis [78]. Our 
data also showed that the presence of VEGF enhances Nrp-1 binding to active 
α5β1 integrin. This enhancing effect of ligand indicates that tumor cell secreted 
VEGF may help to stabilize the complex formation between Nrp-1 and α5β1, thus 
stabilizing tumor cell-endothelial cell adhesion and facilitating tumor cell 
extravasation during metastasis.  
The role of trans-Nrp/integrin interaction was initially reported in 
pathological context in tumor extravasation during metastasis. However, a 
functional and physical connection between Nrp and integrin signaling has not 
been determined in physiological context. While α5/α6 integrin intracellular 
domains interact with GIPC, no other integrin possesses a GIPC binding motif 
[88]. Thus, it is not the intracellular, but ECD-mediated interactions have broad 
implications for Nrp/integrin interactions. Based on these ideas, we want to ask 
can we generalize Nrp1/a5b1 integrin interaction to other physiological context? 
Indeed, a phase I clinical study suggests a correlation between Nrp1 and aIIbb3 
integrin. A single-agent phase I dose escalation study was initiated in patients 
with solid tumors to evaluate the efficacy of anti-Nrp1 monoclonal antibody 
administration [144]. This antibody is MNRP1685A, which binds to Nrp1 b1b2 
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domain and blocks VEGF-A binding. They found a side effect along with the 
antibody administration is platelet count reduction. Mechanistic evaluation 
attributes this side effect to aberrant αIIbβ3-mediated platelet activation and 
aggregation, suggesting a potential role for endothelial-expressed Nrp function in 
platelet coupling.  
In the studies of platelet-endothelial cell/tumor cell interactions, cell 
surface receptors mediating these direct contacts received extensive studies, 
including αIIbβ3 integrin [145], P-selectin [146-148] and αvβ3 integrin [149]. 
Recently, additional receptor interacting pairs have been identified, e.g., Nrp-1 
and integrin interacting pairs. The heterodimeric integrin family can be divided 
into several subfamilies, each of which is defined by a common β subunit [150], 
like the β1 subfamily, β2 subfamily and β3 subfamily. The β3 integrins have been 
shown to be expressed in invasive melanomas and were expressed exclusively 
in tumorigenic melanoma cells [151], indicating that β3 integrins could serve as a 
marker of aggressive melanoma cells. Nrp-1 expression by itself in the absence 
of VEGFR-2 has been shown to be sufficient to promote melanoma invasiveness 
and this Nrp-1-dependent promotion requires Akt phosphorylation and activation 
[152], which is also a downstream signaling molecule for β3 integrins. Since Nrp-
1 is a signal transduction-incompetent transmembrane receptor, based on the 
above functional overlapping as well as the crosstalk in the downstream signaling 
molecules, β3 integrins can serve as candidates of signal-transducing co-
receptor for Nrp-1 in aggressive melanomas. Moreover, in the phase I clinical 
study, the administration of a neutralizing anti-Nrp-1 antibody in vivo in patients 
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results in a transient thrombocytopenia through increasing αIIbβ3 integrin 
mediated platelet aggregation, shows a direct correlation between Nrp-1 and 
αIIbβ3 integrin.   
 Nrp-1 is a vertebrate type I transmembrane glycoprotein consisting of a 
relative large extracellular domain, a single transmembrane domain and a small 
cytodomain containing 44 amino acids [1]. Integrin αIIbβ3 is a receptor for 
multiple plasma adhesive proteins, including fibrinogen, vWF, fibronectin and 
vitronectin and mediates platelet aggregation through the bridging matrix 
proteins. The bleeding disorder disease Glanzmann Thrombasthenia results from 
the lack of platelet aggregation because of the inherited abnormal αIIbβ3 integrin 
number and function [153]. Conversely, extra platelet aggregation mediated by 
αIIbβ3 integrin can cause thrombi in the arterial circulation [154]. Close 
examination of the intracellular C-terminus suggests a lack of the consensus 
GIPC binding motif in αIIb integrin, indicating that there is no GIPC coupled 
intracellular association between Nrp-1 and αIIbβ3 integrin and ECD-mediated 
interaction underlies broader physiological implications between Nrp-1 and 
αIIbβ3 integrin.  
In the present study, we demonstrated that the extracellular domain of 
Nrp-1 specifically interacts with that of αIIbβ3 integrin in an integrin activation-
dependent manner. The trans-Nrp-1/αIIbβ3 integrin interaction supports both 
CHO cell and platelet adhesion to Nrp-1 ECD. Moreover, this interaction 
enhances ADP-induced platelet aggregation, through either bridging mechanism 
similar to that executed by fibrinogen or Nrp-1-induced αIIbβ3 clustering. The 
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enhancing effect requires the multivalent property of Nrp-1 dimerization induced 
by VEGF binding. These results demonstrate a potential trans-interaction 
between αIIbβ3 integrin and Nrp-1 in mediating communication between platelets 
and other cells, including endothelial cells and tumor cells in blood circulation.  
Results 
Integrin αIIbβ3 binds to Nrp-1 via direct link between the extracellular 
domains 
αIIbβ3 integrin is an obligatory mediator for physiological platelet 
aggregation [155, 156] and firm adhesion to ECM and endothelial cells also 
involves αIIbβ3 integrin-mediated bridging mechanism [149]. Communication 
between platelets and endothelial cells contributes to the roles of platelets not 
only in hemostasis and thrombosis, but also in facilitating tumor dissemination 
and transmigration during metastasis. During tumor dissemination in the blood 
circulation, tumor cells produce a prothrombotic microenvironment through 
releasing cytokines and growth factors to ultimately activate platelets and induce 
platelet aggregation. The interactions between tumor cells and platelets are 
reciprocal and adhesion molecules mediating platelet/endothelial cell or tumor 
cell interactions are now receiving systematic studies aimed to develop anti-
platelet drug selectively targeting tumor cell-induced thrombosis. Based on the 
coupling between Nrps and integrins recognized under multiple pathological 
conditions and the correlation between aberrant platelet activation and anti-Nrp-1 
monoclonal antibody (mAb) administration, we hypothesize that a direct physical 
association between Nrp-1 and αIIbβ3 integrin in the ECD underlies their 
functional integration in platelet physiological function. To delineate the direct 
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association, binding of AP (alkaline phosphatase) tagged Nrp-1 (AP-Nrp-1) to the 
immobilized purified human αIIbβ3 integrin was analyzed (Figure 4.1). The 
canonical Nrp-1 ligand VEGF [1] serves as the positive control. In the 
experiment, divalent cations, including Ca/Mg (-Mn group) and Mn (+Mn group), 
were applied. Ca/Mg have been demonstrated to coordinate and stabilize ligand 
binding to the integrin ligand-binding pocket but do not activate integrins [157]. 
Mn binding artificially switches the conformation to a high affinity state for ligand 
binding, mimicking but bypassing the requirement for inside-out activation 
signaling pathways [94, 101]. What’s more, the fact that Mn can potentiate 
platelet aggregation through activating αIIbβ3 integrin without causing secretion 
makes Mn an ideal platelet agonist in studying adhesive proteins involved in 
platelet adhesion [158]. Compared to BSA negative control, inactive αIIbβ3 
integrin in the presence of Ca/Mg (-Mn group) does not show interaction with 
Nrp-1; whereas Mn activation (+Mn group) induces significant and dramatically 
enhanced binding to AP-Nrp-1, indicating that there is indeed a direct physical 
interaction between Nrp-1 and αIIbβ3 integrin in the ECD and this specific 
association is integrin activation dependent. αIIbβ3 integrin does not bind soluble 
fibrinogen on resting platelet; whereas platelet activation by ADP activates αIIbβ3 
integrin and enhances its binding to soluble fibrinogen [159]. Thus, αIIbβ3 
integrin activation is a prerequisite for Nrp-1 binding, the same as that for integrin 
ligand fibrinogen binding.  
Ligands differentially affect Nrp-1/αIIbβ3 integrin ECD interaction 
 We next tested the effect of the addition of Nrp-1 and αIIbβ3 integrin 
ligands, VEGF and fibrinogen respectively, on the interaction. Interestingly, we 
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noticed distinct effects of ligands; while VEGF significantly enhanced the 
interaction, fibrinogen had no effect (Figure 4.2). Thus, enhancement of the 
Nrp/integrin ECD interaction is specific to only certain pairings of ligand and 
ECM. Compared to the enhancing effect of fibronectin to Nrp-1/α5β1 integrin 
association, fibrinogen may not interact with Nrp-1. The minimal structure 
essential for integrin/fibrinogen binding is the Arg-Gly-Asp (RGD) sequence. 
Using the four amino acid peptide RGDS with minimal integrin binding structure, 
we found that the binding of αIIbβ3 integrin to Nrp-1 is not affected, implicating 
that Nrp-1 binds to the site other than the canonical ligand binding pocket on 
αIIbβ3 integrin. Thus, targeting specific Nrp-1/αIIbβ3 integrin interaction would 
not interfere with normal ligand binding to integrin and other important aspects of 
integrin function, e.g., platelet clotting. The current anti-platelet drug that 
interrupts fibrinogen/αIIbβ3 integrin interaction for long-term, would cause severe 
problem in hemostasis, e.g., bleeding [160]. The enhancing effect of VEGF 
suggests that Nrp-1/VEGF signaling may crosslink with αIIbβ3 integrin signaling 
in platelet function.  
Nrp-1/αIIbβ3 integrin ECD association supports cellular adhesion in trans 
Nrp-1 was first discovered as a cell adhesion molecule [43, 79]. The 
expression of Nrp-1 granted fibroblasts adhesiveness through homo- or hetero-
philic interaction with a protease-sensitive molecule [79]. The adhesive site of 
Nrp-1 was later on mapped to the coagulation factor-like b1b2 domains [80]. To 
corroborate the functional implications of this specific physical association, we 
tested this interaction in cellular context using αIIbβ3-expressing CHO cells [100]. 
CHO cells with or without the expression of αIIbβ3 were labeled with fluorescent 
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dye and incubated with Nrp-1 affinity plates. Fluorescence of the bound cells was 
quantified using a fluorescence plate reader and converted to the absolute 
number of adherent cells. Through subtracting the binding signal of the αIIbβ3 
integrin-expressing CHO cells by that of the CHO-parental cells, we generated 
the adhesion data. We observed robust and specific binding to Nrp-1 by the 
αIIbβ3-expressing cells when compared to negative (BSA) and positive 
(fibrinogen) controls (Figure 4.3). Importantly, this interaction was inhibited by 
preincubation of the cells with either a function-blocking anti-β3 monoclonal 
antibody 7E3 or a disintegrin peptide Echistatin (Ech) (Figure 4.3). 7E3 has been 
shown to inhibit platelet aggregation and interfere with platelet adhesion to the 
intact endothelium in the microvasculature via inhibition of αIIbβ3 integrin [161]. 
Echistatin is a 49 amino acid peptide containing the active integrin binding RGD 
site and has been shown to inhibit ADP-induced platelet aggregation [162]. The 
blocking effect of αIIbβ3 integrin inhibitors demonstrated the specificity of the 
interaction. Thus, Nrp-1 supports cellular adhesion via a direct interaction with 
αIIbβ3 integrin.  
Nrp-1/αIIbβ3 integrin interacts in the context of platelet adhesion 
To further examine the physiological relevance of this interaction, we 
measured binding of Nrp-1 to platelets. αIIbβ3 integrin, when activated, is critical 
for platelet aggregation [163] and firm adhesion to ECM [164] as well as 
endothelial cells [165] during hemostasis and thrombosis. Rest human platelets 
express approximately 80,000 copies of cell surface αIIbβ3 integrin, which is the 
major cell surface receptor on platelets [166]. In the experiment, fresh human 
platelets were isolated from whole blood and labeled with the acetomethoxy 
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derivative of calcein (Calcein-AM). Platelets were then incubated with Nrp-1 
affinity plates, and bound platelets were quantified using a fluorescence plate 
reader. We observed robust, activation-dependent binding of platelets to the Nrp-
1 extracellular domain (Figure 4.4A). The interaction was specifically inhibited by 
either the functional-blocking anti-β3 antibody 7E3 or the disintegrin, Echistatin, 
which is a potent inhibitor of platelet activation via inhibition of αIIbβ3. Fibrinogen, 
a dimer with multiple binding site for αIIbβ3 [167], mediates ADP-induced platelet 
aggregation [168-171] through bridging αIIbβ3 integrin from two opposing 
platelets [165, 172] and induces αIIbβ3 integrin clustering in the presence of Mn 
activation [173]. Fibrinogen serves as the positive control in this adhesion assay 
and shows strong adherence to human platelets in the presence of Mn activation. 
Thus, Nrp-1, an adhesive molecule originally identified to mediate fibroblast 
adhesion, may also serve as the platelet αIIbβ3 ligand. To test the generality of 
the interaction, we also tested the binding of mouse platelets to Nrp-1. As with 
human platelets, we observed robust and specific adhesion of mouse platelets 
with Nrp-1, which was specifically inhibited by 7E3 and Echistatin (Figure 4.4B). 
As further confirmation of the specific role of αIIbβ3, we also tested the adhesion 
of platelets isolated from β3-knockout mice [174]. Although these mice are viable 
and fertile, they demonstrate platelet aggregation defects as well as 
osteosclerosis [175]. We saw a complete loss of Nrp-1 binding to these platelets 
(Figure 4.4C). Thus, both pharmacological and genetic methods demonstrate 
that Nrp-1 supports platelet adhesion via direct interaction with αIIbβ3. The action 
of Nrp-1 mimics that of αIIbβ3 extracellular ligand fibrinogen.  
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Coagulation factor-like domains b1b2 mediate Nrp-1/αIIbβ3 integrin ECD 
interaction 
 The observation that the direct physical interaction can support the cellular 
adhesion prompts us to identify the motifs in the Nrp-1 ECD responsible for 
interacting with αIIbβ3 integrin. Based on the similarities in sequence and 
structure as well as ligand binding properties and functions in signaling, the Nrp-1 
ECD was subdivided into the three domain combinations: a1a2, b1b2 and c 
domains (Figure 4.5A). The Nrp-1 ECD was found to bind directly to αIIbβ3 ECD 
using its extracellular b1b2 domains, whereas neither a1a2 nor c domains bound 
(Figure 4.5B). Soluble Nrp-1 b1b2 protein functions as a competitor against Nrp-
1 ECD and blocks the binding to αIIbβ3 integrin. These data suggest that the 
coagulation factor-like domains b1b2 of Nrp-1 are essential and sufficient for 
mediating the demonstrated Nrp-1/αIIbβ3 integrin direct physical interaction in 
the extracellular domain.  
Effect of Nrp-1 on platelet activation 
To further test the effect of Nrp-1 on platelet activation, we performed 
platelet aggregometry assay using optical aggregometer with isolated mouse 
platelets, measuring the optical density of a solution of platelets in response to 
stimulation [176]. Platelet αIIbβ3 integrin classically and practically requires 
agonist activation, e.g., ADP, to recognize and bind ligands, e.g., fibrinogen. We 
tested the ability of Nrp-1 to induce platelet aggregation on its own or to modulate 
αIIbβ3-dependent aggregation in response to activation by ADP. Since Nrp-1 
b1b2 domains are responsible for binding to αIIbβ3 integrin, we verified the effect 
of soluble Nrp-1 b1b2 protein. We observed that Nrp-1 does not activate platelets 
either alone or upon stimulation with ADP (Figure 4.6A). Since VEGF binding 
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results in Nrp-1 dimerization and enhances the interaction with αIIbβ3, we next 
tested if a Nrp-1/VEGF complex effected platelet contrast. In contrast to either 
Nrp-1 or VEGF alone, which had no effect, the complex showed significant ADP-
dependent activation of platelet aggregation (Figure 4.6A). Importantly, this 
activity was completely inhibited by pre-incubation of mouse platelets with 
Echistatin (Ech), indicating the specificity of the mechanism of action (Figure 
4.6B). Thus, interaction with Nrp-1 promotes platelet adhesion, and the VEGF-
bound complex of Nrp-1 is able to enhance αIIbβ3-driven platelet aggregation 
opening up new avenues for understanding the physiological function of Nrp-1 in 
the cardiovascular system.  
Discussion 
 Here we report that Nrp-1 and αIIbβ3 ECDs directly interact. This 
interaction is mediated by the Nrp-1 b1b2 ligand binding domains and is integrin 
activation-dependent. We further demonstrate that the Nrp-1 ligand VEGF 
promotes the interaction of Nrp-1 and αIIbβ3. This ECD-mediated interaction is 
critical for Nrp-1 promoted integrin function in cellular context. Integrin αIIbβ3 
supports direct cellular adhesion on Nrp-1 ECD in the absence of additional 
factors, compared to the promoting effect of Nrp-1 in α5β1 integrin-mediated 
cellular binding to ECM in trans. We also extended the work to demonstrate the 
physiological implications of this trans-interaction in platelet function by showing 
that VEGF-bound complex of Nrp-1 is able to enhance ADP-induced platelet 




 Platelets recruitment to the sites of damaged vessels plays important roles 
in preventing hemorrhage after tissue trauma and vascular injury during 
hemostasis [18, 177]. The emigrating platelets adhere to the sub-endothelial 
matrix and activated endothelial cells through sequential interactions between 
multiple platelet adhesion molecules and their specific ligands. A number of 
studies extensively demonstrated the platelet receptors involved in 
communication with endothelium, e.g., platelet P-selectin mediates rolling of 
activated platelets on high endothelial venules [178] and platelet αIIbβ3 integrin 
mediates firm adhesion of human platelets to saphenous vein endothelial cells 
[179]. Endothelial αvβ3 integrin mediates platelet/endothelium adhesion, which 
can be blocked by anti-αvβ3 antibodies [180, 181]. Besides the well-documented 
adhesion molecules, in current study, we identified Nrp-1, which is expressed 
either physiologically on endothelial cells or pathologically on tumor cells as a 
novel counter-receptor for platelet αIIbβ3 integrin. 
 Many tumor cells express high levels of Nrp-1 on the cell surface, e.g., 
231 breast carcinoma cells and PC3 prostate carcinoma cells [9, 182-184]. 
These tumor cells express Nrp-1 as the only VEGF receptor to mediate VEGF-
induced chemotaxis. However, the lack of the intrinsic enzymatic domain in the 
intracellular part of Nrp-1 makes it essential for Nrp-1 to associate with other co-
receptor to transduce VEGF signals. Integrins, as a candidate, have been 
reported to interact with VEGF and modulate VEGF-induced angiogenic 
signaling. For example, αvβ3 integrin directly binds to VEGF to support 
endothelial cell adhesion to immobilized VEGF and facilitates endothelial cell 
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survival [185]; α9β1, which also interacts with VEGF, acts coordinately with 
VEGFR-2 in the form of a macromolecular complex to mediate endothelial cell 
adhesion and migration on immobilized VEGF [186]. Consistent with those 
studies, we observed an enhancing effect of VEGF to the direct Nrp-1/αIIbβ3 
integrin interaction. This enhancing effect indicates that VEGF may also directly 
interact with αIIbβ3 integrin. The enhancing effect of VEGF may attribute to the 
following two reasons: 1) VEGF binding induces a ternary complex formation to 
stabilize αIIbβ3/Nrp-1 direct association; 2) VEGF-induced Nrp-1 dimerization 
promotes the association with αIIbβ3 integrin. In contrary to the promoting effect 
to Nrp-1/αIIbβ3 association, it has been demonstrated that full length Nrp-1 and 
αvβ3 integrin associates in a VEGF-dependent manner [137], indicating that Nrp-
1/VEGF signaling may crosslink with β3 integrin signaling in platelet physiology. 
In contrast to VEGF, integrin ligand fibrinogen, when applied, did not exert any 
effect in Nrp-1/αIIbβ3 interaction, demonstrating that Nrp-1 and fibrinogen 
binding sites locate at the distinct sites of αIIbβ3 integrin ECD. The observation 
that VEGF-bound complex of Nrp-1 enhances ADP-dependent platelet 
aggregation suggests that the oligomerized Nrp-1 has similar effect as fibrinogen 
in αIIbβ3 integrin-driven platelet aggregation. Preincubation of mouse platelets 
with either fibrinogen or complex of Nrp-1 and VEGF promotes ADP-dependent 
platelet aggregation.  
 In summary, our results demonstrate that Nrp-1 directly interacts with 
platelet integrin αIIbβ3 through its extracellular b1b2 domains in an integrin 
activation-dependent manner. Based on the ubiquitous expression of Nrp-1 in 
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endothelial cells and tumor cells, the trans-Nrp-1/αIIbβ3 interaction may 
contribute to platelet-endothelial cell interaction during hemostasis and platelet-
tumor cell adhesion during hematogenous spreading and metastasis. Detailed 
studies of this interaction at the molecular and structural level will provide the 
molecular mechanism for developing anti-platelet drugs targeting αIIbβ3-driven 




























Figure 4.1 Nrp-1 physically interacts with αIIbβ3 integrin ECD. Recombinant 
human αIIbβ3 integrin ECD (αIIb subunit residues: Met1-Arg993; β3 subunit 
residues: Gly27-Asp718) (R&D systems) coated on 96-well plate shows 












Figure 4.2 Ligands distinctly affect Nrp-1/αIIbβ3 ECD interaction. VEGF 
specifically enhances the binding of Nrp-1 to αIIbβ3, whereas fibrinogen (Fg) and 











Figure 4.3 αIIbβ3 integrin-expressing CHO cells adhere to purified immobilized 
Nrp-1. Calcein-AM labeled CHO cells stably expressing αIIbβ3 integrin show 
integrin activation-dependent interaction with Nrp-1. This interaction is inhibited 
by β3 integrin function-blocking antibody 7E3 and disintegrin peptide Echistatin 








Figure 4.4 Platelets interact with Nrp-1. A) Human platelets adhere to Nrp-1 in an 
activation-dependent fashion. Both 7E3 and Echistatin block the adhesion, 
demonstrating that αIIbβ3 specifically mediates the interaction. Fibrinogen (Fg) 
serves as a positive control. B) Similar to human platelets, wild-type mouse 
platelets specifically adhere to Nrp-1. C) In contrast, β3-knockout platelets do not 











Figure 4.5 The Nrp-1 ECD directly interacts with the αIIbβ3 ECD through its b1b2 
domains. A) Schematic representation of Nrp-1 extracellular domains. B) The 








Figure 4.6 ADP-dependent platelet aggregation is induced by Nrp-1/VEGF. A) 
The complex of Nrp-1 and VEGF induces ADP-dependent platelet aggregation, 
whereas each individual protein does not. Fibrinogen serves as a positive 
control. B) Platelet aggregation, induced by the addition of Nrp-1/VEGF complex 







CHAPTER FIVE Molecular interactions between Nrp-1 and angiogenesis 
and axon guidance molecules 
 
Introduction 
 Nrp-1 was initially identified in the optic tectum of Xenopus and 
functionally characterized as a receptor for Sema3 family ligands in neurons. 
Nrp-1 was then identified as a VEGF isoform-specific receptor and functions in 
regulating VEGF-induced angiogenesis.  
The two conserved Nrp family members, Nrp-1 and Nrp-2, share the same 
overall domain structure and 44% homology of the amino acid sequence, leading 
to their overlapping but unique functions and ligand binding properties and 
specificities. Both of Nrp-1 and Nrp-2 are type I transmembrane proteins and 
function as pleiotropic co-receptors in cellular signaling, physically coupling with 
VEGFRs and other adhesive and signaling receptors with Nrp-1 specifically, 
taking the cardiovascular system for example, functioning in blood vessel 
endothelial cells; whereas Nrp-2 in lymphangiognesis.  
Ligand binding is the critical initial step in signal transduction. As “co-
receptors”, Nrps have been shown to enhance binding affinity of the ligands to 
their cognate receptors with the N-terminal extracellular domains are responsible 
for ligand coupling. In Nrp-1, extracellular a1 domain is the binding site for 
Sema3 [47]. The b1 domain was extensively shown as the binding site for the 
specific C-terminal residues of both VEGF and furin-processed Sema3 to 
mediate their competitive binding and the opposing effects in angiogenesis [72, 
81, 133, 187, 188]. The extracellular c domain is not directly involved in ligand 
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binding but critical for ligand-dependent signaling [52]. The single 
transmembrane helix contains a well-conserved double GxxxG motif, which 
possesses an inherent dimerization potential in a ligand-independent manner 
and may mediate selective recruitment of other membrane receptors in signaling-
competent complex assembly [189]. The intracellular domain of Nrp-1 binds to 
the adaptor protein GIPC through its C-terminal SEA motif [22].  
Through coordinating the extracellular and intracellular domains, Nrp-1 
promotes signaling pathway activation by recruiting and presenting ligands to 
other cell surface receptors via enhancing ligand-binding affinity and stabilizing 
the assembly of the active signaling complex, or facilitating receptor 
internalization and recycling. Ligand coupling to Nrp-1 serving as the critical initial 
steps in Nrp-1 promoted signaling activation in the cardiovascular system and 
neuronal development, receives extensive characterization. But the specific Nrp-
1/VEGF interaction and the molecular mechanisms underlying the high affinity 
binding of Sema3 to Nrp-1 are still elusive.  
Our data demonstrate that a conserved acidic residue in the exon 7-
encoded region contributes to the selective binding to Nrp-1 through negatively 
regulating the binding of VEGF to Nrp-2 and the polybasic residues in Nrp-1 b1 
ligand-binding pocket positively contribute to the binding of VEGF to Nrp-1; in 
Sema3 binding, both the C-terminal arginine and its proximal helical region in the 




Mechanism underlying VEGF binding selectivity and specificity to Nrp-1 
b1b2 domains versus Nrp-2 b1b2 domains (Results presented are adapted 
from [93].) 
Introduction 
 Nrp-1 is an essential type I transmembrane receptor for VEGF-mediated 
angiogenesis [10]. The critical role of Nrp-1 in cardiovascular development is that 
knockout of Nrp-1 in vivo causes embryonic lethality due to severe and widely 
distributed cardiovascular defects [32, 38]. In angiogenesis, Nrp-1 functions 
through enhancing ligand-binding affinity to VEGFR-2 and stabilizing the 
competent angiogenic complex formation of VEGF/VEGFR-2/Nrp-1 [190]. 
 VEGF family members are diversified by alternative splicing [191]. 
Alternative splicing generates VEGF isoforms with variant diffusibility and binding 
affinity to Nrp-1 [109]. Among all the isoforms, mouse VEGF164, which has a 
homolog VEGF165 in human, is the most potent angiogenic stimulator and 
contains an exon7 and 8-encoded heparin binding domain (HBD) [192, 193], 
through which VEGF165 binds to Nrp-1 b1 domain [48, 58, 66].  
 Exon 8-encoded C-terminus is conserved in all proangiogenic VEGF 
isoforms except for the alternative spliced VEGF165b, which carries regions 
encoded by exon 9, instead of exon 8 and demonstrates reduced angiogenic 
potential and does not bind to Nrp-1 [194, 195]. Further, a short peptide 
mimicking VEGF exon 8, Tuftsin, inhibits VEGF binding to the ligand-binding 
pocket of Nrp-1 b1 domain [81]. Moreover, exon 8-encoded C-terminus has been 
demonstrated in all current known proteins and peptides that bind to Nrp-1 [72, 
81, 133, 188]. These data establish a critical role of exon 8-encoded C-terminus 
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in Nrp-1 binding. HBD-encoding exon 7 also contributes to Nrp/VEGF binding. 
Exon 7-encoded region was initially shown to define the isoform-specific binding 
of Nrp-1 to VEGF164 not VEGF120 [66]. However, it was currently clearly 
demonstrated that both VEGF164 and VEGF120 bind to Nrp-1, although with 
distinct binding affinity [196], indicating the important but different roles of exon 7 
and 8-encoded sequences in Nrp/VEGF binding.  
 Nrp-2 is another Nrp family member sharing 44% amino acid sequence 
homology and similar overall domain structure and organization [8]. Nrp-1 and 
Nrp-2 have redundant and unique functions with Nrp-1 mainly participating in 
VEGF-stimulated blood vessel endothelial cell angiogenesis [66]; whereas Nrp-2 
primarily mediating VEGF-C-induced lymphangiogenesis [197]. Differential ligand 
binding and specific spatial-temporal expression of Nrps are important regulatory 
mechanism controlling Nrp functions [29]. Unlike the well-studied differential 
VEGF binding to distinct VEGFRs, the molecular basis for specific VEGF binding 
to Nrps has not been elucidated yet.  
 To characterize the nature and basis for the potent and specific VEGF 
binding to Nrps, we performed in vitro direct protein-protein interaction assay and 
have demonstrated that VEGF selectively binds to Nrp-1 versus Nrp-2 using its 
specific exon 8-encoded amino acid residue.  
Results 
VEGF selectively binds to Nrp-1 versus Nrp-2 
 Nrp-1 and Nrp-2 share 44% amino acid sequence identity and bind to 
VEGF family members and Sema3s in an isoform-specific manner. While Nrp-1 
binds to VEGF, VEGF-B, VEGF-C, VEGF-D, VEGF-E, PlGF and Sema3A, 
 
 73 
Sema3C and Sema3F; Nrp-2 binds to all the above ligands except for VEGF-B, 
VEGF-E and Sema3A [30, 71, 198]. Nrps interact with Sema3s with binding 
specificity. While Sema3C equally binds to Nrps, Sema3F binds to Nrp-2 with 10 
fold higher affinity relative to Nrp-1 [198]. To test if this is true for VEGF/Nrp 
binding, we performed in vitro protein binding assay and demonstrated an 
approximately 15 fold higher retention of Nrp-1 by VEGF (refer to WT VEGF) in 
contrast to Nrp-2 (Figure 5.1), indicating the binding selectivity of VEGF to Nrp-1 
in contrast to Nrp-2. To understand the physical basis for Nrp binding of VEGF, 
we examined the published crystal structure of the VEGF HBD in complex with 
Nrp-1 b1 domain (Figure 5.2). In the crystal structure, VEGF HBD (green and 
yellow) fully engages the Nrp-1 b1 domain (cyan) and both exon 7 and 8-
encoded regions (HBD) participate in the formation of the extended 
intermolecular interaction interface between VEGF and Nrp-1, indicating the 
importance of both exon 7 and 8-encoded residues in HBD-Nrp-1 b1 complex 
formation. Moreover, in vitro direct protein-protein interaction assay showed that 
both VEGF164 and VEGF120 bound Nrp-1 with 7 fold higher affinity for VEGF164 
versus VEGF120 [93]. Both isoforms contain exon 8-encoded region and differ 
only in the exclusion of exon 7 in VEGF120, confirming the essential role of exon 8 
and the involvement of exon 7 in determining VEGF/Nrp-1 interactions.   
Exon 8-encoded C-terminus of VEGF possesses a conserved acidic residue 
negatively regulating the binding to Nrp-2 
 To further characterize the physical and molecular basis for Nrp/VEGF 
interactions, we did both close examination of the crystal structure of VEGF 
HBD-Nrp-1 b1 complex and sequence alignments of VEGF HBD across 
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vertebrate species. Close examination of the crystal structure and previous in 
vitro protein interaction assay demonstrate that exon 8-encoded C-terminal 
arginine (R164) of VEGF mediates high affinity Nrp-1 binding and exon 7-
encoded glutamate-154 (E154) contributes to Nrp-1 binding [93]. In the crystal 
structure, R164 is fully engaged by Nrp-1 with 274 Å2 buried surface area at the 
interface, forming a salt bridge and hydrogen bond network with residues in the 
b1 domain. Site-directed mutagenesis together with in vitro protein interaction 
assay confirmed the importance of the above molecular interactions through 
either mutating R164 to alanine (R164A) or adding C-terminal dialanine 
(R164R+AA) or producing charge reversal (R164E). Moreover, exon 7-encoded 
E154 was found to directly and physically engage threonine-299 (T299) in Nrp-1 
b1 ligand-binding pocket in the crystal structure. In vitro protein interaction assay 
confirmed this interaction through mutating E154 to alanine (E154A). Besides the 
above previously reported critical residues, sequence alignment identified several 
conserved acidic or basic residues in VEGF HBD (Figure 5.3). In exon 8-
encoded region, lysine (K), proline (P) and C-terminal arginine (R164) of VEGF 
are very well conserved across species and have been reported before to be 
essential for Nrp binding [199]. To give a comprehensive characterization of the 
exon 8-encoded C-terminal residues, we analyzed the contribution of 
uncharacterized aspartic acid-160 (D160) to Nrp binding by mutating D160 to 
alanine (D160A) or producing charge reversal (D160K). Through the in vitro 
protein interaction assay, we observed that retention of neither VEGF mutants by 
Nrp-1 changed relative to WT VEGF (Figure 5.4A). Strikingly, both VEGF 
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mutants (D160A and D160K) demonstrate significantly enhanced binding to Nrp-
2 compared to WT VEGF (Figure 5.4B), indicating that the exon 8-encoded D160 
of VEGF contributes to Nrp-1 binding selectivity via an electrostatic repulsion with 
Nrp-2. Next, we try to define the molecular interactions formed by D160 of VEGF 
at the interaction interfaces with Nrp-1 b1 domain. Utilizing the PDB file 
generated along with the crystal structure model discussed above, we analyzed 
the protein interfaces using PISA software and found the residues making 
hydrogen bonds (Table 5.1) and salt bridges (Table 5.2) between VEGF HBD 
and Nrp-1 b1 domain in the complex. D160 residue is not involved in those 
interfacing residues making either hydrogen bonds or salt bridges with Nrp-1, 
explaining the reason why D160 mutants did not affect Nrp-1 binding. However, 
close examination of the crystal structure demonstrates that it is in close 
proximity to the residues of L1 loop (loop1) of Nrp-1 b1 domain (Figure 5.5), 
tyrosine-297 (Y297), serine-298 (S298), threonine-299 (T299) and asparagine-
300 (N300), which are not only important for composing the b1 ligand-binding 
pocket, but also contributing to interfacing hydrogen bond formation. Sequence 
alignment identified the corresponding region in Nrp-2 includes residues aspartic 
acid-301 (D301), glycine-302 (G302) and arginine-303 (R303) (Figure 5.6). 
Superimposition of Nrp-1 and Nrp-2 b1 domains, which share 52% sequence 
homology, reveals a similar overall architecture with the unique amino acids of 
the L1 loops demonstrated with side chain (Figure 5.7). Although we did not get 
the crystal structure of VEGF HBD in complex with Nrp-2 b1 domain, the similar 
architecture of Nrp-1 and Nrp-2 b1 domain indicates that similar to Nrp-1 L1 loop, 
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D160 of VEGF HBD localizes in close proximity to the residues of Nrp-2 L1 loop, 
specifically tyrosine-299 (Y299), serine-300 (S300), aspartic acid-301 (D301), 
glycine-302 (G302) and arginine-303 (R303), which are aligned to YST-N (297-
300) residues in Nrp-1 L1 loop. Inclusion of the opposing charged residues D301 
and R303 may account for the electrostatic repulsion between D160 of VEGF 
HBD and Nrp-2 b1 domain.  
The polybasic residues in Nrp-1 b1 domain contribute to the selective 
VEGF binding 
 The predominant VEGF binding site on Nrp-1 has been localized to 
domain b1 [48, 200]. Sequence alignment of the b1 domain identified 52% 
homology between Nrp-1 and Nrp-2, higher than the 44% identity of the overall 
amino acid sequence. Besides the conservation, several variations were 
identified (Figure 5.6). Those residues can be divided into two categories: those 
that are not well conserved in either Nrp-1 or Nrp-2, and those that are distinct 
between Nrp-1 and Nrp-2 but well conserved within each ortholog. We 
hypothesize that residues in the 2nd category may underlie the specific Nrp-
1/VEGF binding, especially residues composing the coagulation-factor loops, L1-
L3 loops, which are utilized for ligand binding by the coagulation-factor domain 
containing proteins, Factor V/VIII [201] or residues surrounding the interloop cleft. 
Based on these ideas, residues that are separately conserved within Nrp-1 and 
Nrp-2 and that are nearby the ligand binding pocket are selected: Nrp-1: 
E285/Nrp-2: R287; Nrp-1: T299N300/Nrp-2: D301G302R303; Nrp-1: 
E304R305/Nrp-2: Q307Q308; Nrp-1: K350K351K352/Nrp-2: Q353N354G355 
(Figure 5.6). Surface representation of the Nrp-1 b1 domain crystal structure 
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demonstrates that the above selected regions localize in close proximity to the 
direct VEGF binding region in three-dimensional structure (Figure 5.8). To test 
our hypothesis, we have designed mutant proteins through swapping the 
selected sequences between Nrp-1 and Nrp-2 to create chimeric receptors. For 
the current study, we chose the swapped L3 mutants of Nrp-1 and Nrp-2 to 
detect the contribution of these residues to VEGF binding specificity. Nrp 
residues that are responsible for the observed specificity would be expected to 
increase mutant Nrp-2 binding to a comparable level as WT Nrp-1 and vice versa 
in Nrp-1 when swapped. Specifically, we made chimeric proteins, Nrp-1-2 
(mutant Nrp-1) and Nrp-2-1 (mutant Nrp-2), through swapping L3 residues of 
Nrp-1 K350K351K352 with that of Nrp-2 Q353N354G355. These chimeric Nrp 
proteins were expressed and immobilized on affinity plates. The binding of 
alkaline phosphatase (AP) tagged VEGF to WT Nrp-1, WT Nrp-2, Nrp-1-2 and 
Nrp-2-1 was measured (Figure 5.9). It was observed that L3 swapping had no 
effect in either Nrp-1 or Nrp-2 binding. Further measurements are needed to 
detect the binding of VEGF to the rest Nrp chimeras with swapping residues of 
L1 and L2 loops and figure out the contribution in the selective VEGF binding to 
Nrps.  
Discussion 
 Here we reported that VEGF selectively binds to Nrp-1 compared to Nrp-
2. Residue D160 at the C-terminus of VEGF, unlike other charged residues 
encoded by exon 8 reported previously, does not directly interact with Nrp-1 but 
negatively modulate the binding to Nrp-2. The polybasic residues in Nrp-1 b1 
domain L3 loop do not contribute to the specific interaction. Together, these data 
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provide a mechanism for selective VEGF binding to Nrps. Using site-directed 
mutagenesis, our data define the specific contribution of VEGF exon 8-encoded 
residues to Nrp binding affinity and specificity. We notice that there are several 
conserved charged residues in the C-terminal region of VEGF encoded by exon 
7 and 8. Previous and our current data well defined the contribution of exon 8-
encoded residues. The rest charged and conserved residues predicted by 
sequence alignment and the interfacing residues predicted by PISA software are 
needed to investigate to facilitate the understanding of the contribution of exon 7-










Figure 5.1 VEGF selectively binds to Nrp-1 versus Nrp-2 detected by plate 
binding assay. WT VEGF shows higher retention of Nrp-1 b1b2 domains relative 















Figure 5.2 Crystal structure of VEGF HBD in complex with Nrp-1 b1 domain. 
Intermolecular complex of VEGF HBD and Nrp-1 b1 domain reveals a full 
engagement and an extended intermolecular interaction interface between VEGF 






Figure 5.3 Alignment of orthologous VEGF exon 7 and 8-encoded domains. 
Sequence alignment of human, mouse, xenopus and zebrafish VEGF C-termini 
shows conservation of acidic (pink) and basic (green) residues that maybe critical 








Figure 5.4 The C-terminal conserved acidic residue aspartic acid-160 (D160) of 
VEGF prevents its binding to Nrp-2 but favors the interaction with Nrp-1. Charge 
reversal (D160K) and removal (D160A) show similar retention of Nrp-1 relative to 
WT VEGF (A), but demonstrate 12-fold higher retention of Nrp-2 compared to 
WT VEGF (B). Data was reported as the mean of duplicate and AP activity of 3 




Table 5.1 Hydrogen bonds formed between VEGF HBD and Nrp-1 b1 domain.  
## Nrp-1 b1 Dist. [18]   VEGF HBD 
amino acid position amino acid position 
1 N 300 3.49 D 142 
2 N 300 2.76 E 151 
3 T 299 2.73 E 154 
4 T 299 3.16 E 154 
5 Y 297 3.17 P 162 
6 Y 353 3.13 R 164 
7 T 349 2.95 R 164 
8 S 346 3.08 R 164 
9 E 348 3.06 R 163 
10 D 320 3.32 R 164 
11 D 320 3.39 R 164 
12 I 415 3.68 R 164 
13 D 320 3.28 R 164 
14 D 320 3.08 R 164 
14 hydrogen bonds are formed between the interfacing residues in the complex 
of VEGF HBD-Nrp-1 b1. The interfacing residues and their amino acid positions 
in the original proteins are shown in the table. The interaction interfaces were 
analyzed using the PISA interaction server using PDB code 4DEQ.   
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Table 5.2 Salt bridges formed between VEGF HBD and Nrp-1 b1 domain. 
##   Nrp-1 b1 Dist. [18] VEGF HBD 
amino acid position amino acid position 
1 E 348 3.06 R 163 
2 E 348 3.61 R 163 
3 E 348 3.86 R 163 
4 D 320 3.32 R 164 
5 D 320 3.39 R 164 
6 D 320 3.28 R 164 
7 D 320 3.08 R 164 
7 salt bridges are formed at the interaction interface of VEGF HBD in complex 
with Nrp-1 b1 domain. They are mainly formed between the C-terminal arginine 
residues of VEGF HBD and the residues within the loop regions forming the 
ligand-binding pocket of Nrp-1 b1 domain. Similarly to Table 5.1, the interfacing 
residues as well as their original positions in the amino acid sequence are shown 
in the table and the interaction interfaces were analyzed using the PISA 





Figure 5.5 Exon 8-encoded C-terminal aspartic acid of VEGF demonstrates close 
proximity to the L1 loop of Nrp-1. The C-terminal aspartic acid-160 (D160, blue) 
of VEGF does not form interfacing interactions with Nrp-1 b1 domain, but localize 
in close proximity to the interacting residues (red) in the Nrp-1 b1 L1 loop in the 







Figure 5.6 Alignment of orthologous Nrp-1 and Nrp-2 b1 domains. Sequence 
alignment identified 52% homology in amino acid sequence between Nrp-1 and 
Nrp-2 b1 domain. There are three loop regions composing the Nrp-1 ligand-
binding pocket, including the highly conserved residues (marked with *) and 
variations, especially the orange region, Nrp-1: E285/Nrp-2: R287; magenta 
region, Nrp-1: T299N300/Nrp-2: D301G302R303; cyan region, Nrp-1: 
E304R305/Nrp-2: Q307Q308; green region, Nrp-1: K350K351K352/Nrp-2: 
Q353N354G355. Below the alignment, a conservation histogram showing 
sequence identity across species is demonstrated. L1-L3 represents the 
coagulation-factor loop 1, loop 2 and loop 3, surrounding the ligand-binding 





Figure 5.7  Superimposition of Nrp-1 (PDB code 1KEX) and Nrp-2 (PDB code 
2QQJ, residues 276-431) b1 domains. The superimposition of the two 
orthologous b1 domains indicates a similar overall architecture between Nrp-1 
and Nrp-2 with root mean square deviation 0.7 Å. The major difference in the 
overall architecture comes from the unique amino acid composition of the L1 
loop, with Nrp-1 T299 and Nrp-2 D301 demonstrated with side chain and 
























Figure 5.8 Surface representation of Nrp-1 b1 domain (PDB code 4DEQ). The 
direct VEGF binding region (gold) is generated based on the hydrogen bond and 
salt bridge forming residues of Nrp-1 demonstrated in Table 5.1 and Table 5.2 
and is closely associated with the selected variations (colored according to 










Figure 5.9 L3 loop swapping does not affect VEGF binding to Nrps. 
Determination of VEGF binding capacity of Nrp-1 and Nrp-2 mutants reveals that 
L3 loop swapping demonstrates neither loss of binding for Nrp-1 nor enhanced 





Mechanism underlying the antagonism of semaphorin 3F C-terminal 
mimicking peptide to VEGF in angiogenesis (Results presented are 
adapted from [73].) 
Introduction 
 Nrps are essential type I transmembrane receptors [10]. At a molecular 
level, Nrp functions through specific physical interactions with the canonical 
ligands Semaphorin 3 (Sema3) and VEGF to mediate axon guidance and 
angiogenesis [10]. In addition to the functions in neurons, an essential role for 
Sema3s in tumor cell and endothelial cell functions have been increasingly 
identified [63, 202-205]. For example, one Sema3 isoform, Sema3F functions as 
a tumor suppressor through inhibiting tumor cell/endothelial cell adhesion and 
migration [63] and maintaining the avascular phenotype of the outer retina [206].  
 Nrp is important for integrating the opposing effects of VEGF and Sema3 
through coordinating the competitive binding of VEGF and Sema3. Nrp-1 b1 
domain contains a binding pocket, which is critical for the competitive binding 
through a conserved C-terminal arginine of VEGF and furin-cleaved Sema3 [72, 
81]. Furin cleavage of Sema3 modulates their activities and functions depending 
on the cleavage sites on Sema3, including the central regions and the C-terminal 
regions. Proteolysis in the central region has been reported to inactivate Sema3 
[65, 75, 207]. However, furin processing at the C-terminal domain exposes the C-
terminal arginine, allowing for competitive Nrp-1 b1 domain binding [72, 74]. 
Endogenous Sema3F has been shown as a potent competitor for VEGF binding 
to Nrp-1 [72]. However, the molecular mechanism of high-affinity binding of 
Sema3F to Nrp-1 has not been determined yet. Here, we demonstrate in situ the 
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mechanism underlying the antagonism of Sema3F to the binding to Nrp-1 by 
VEGF in angiogenesis using a homodimeric peptide mimicking the furin-
processed C-terminal domain of Sema3F (C-furSema) (Figure 5.10).  
Results 
C-furSema is a potent inhibitor for VEGF induced VEGFR-2 
phosphorylation 
 To determine the potency of C-furSema function in inhibiting VEGF 
binding to Nrp-1, we examined its ability to inhibit VEGF stimulated VEGFR-2 
phosphorylation in cellular context, since Nrp-1 is essential for VEGF stimulated 
VEGFR-2 activation [114]. We used PAE cells stably expressing Nrp-1 and 
VEGFR-2 to measure the ability of C-furSema to inhibit VEGF mediated 
phosphorylation of VEGFR-2 at Tyr-1175 site. Compared to VEGF stimulation 
alone, C-furSema dramatically inhibited VEGF stimulated VEGFR-2 activation 
(Figure 5.11A). C-furSema alone has no effect in VEGFR-2 phosphorylation 
(Figure 5.11A). These data suggest that C-furSema is a potent inhibitor of Nrp-1 
mediated angiogenic activation of endothelial cells in situ. This inhibitory potency 
may attribute to the dual engagement of Nrp-1 by the dimeric property of C-
furSema.  
The N-terminal helical region significantly contributes to the potency of C-
furSema 
 According to the amino acid sequence alignment of human, rat, mouse, 
cow, dog, chicken, and zebrafish orthologs done to Sema3F [73], both the C-
terminus and the N-terminus of C-furSema are conserved during evolution. 
Furthermore, it has been shown that the N-terminal 11 amino acids flanking 
around the cysteine residue has an α-helical propensity based on the secondary 
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structure predictions [73]. Importantly, this is the only predicted structured region 
in the C-terminal basic domain of Sema3. Based on this, we hypothesize that 
besides the C-terminal arginine that is critical for Nrp-1 binding [72, 93], the N-
terminus may also be involved in binding to Nrp-1 and the essential binding 
factors include the predicted helix and the conserved cysteine residue necessary 
and sufficient for dimerization. To test the effect of the predicted α-helix, a protein 
with half of the predicted helix deleted but retained dimerization was produced 
(∆N-C-furSema) to compare the potency for Nrp-1 binding with that of C-
furSema. It has been shown that ∆N-C-furSema has 5 fold less potency 
(IC50=111±21nM) than C-furSema (IC50=25±3nM) [73]. Moreover, the conserved 
cysteine of C-furSema was shown to be required both for oligomerization and 
stabilization of the N-terminal helix motif [73]. These data suggest the significant 
contribution of the N-terminal region of the C-terminal basic domain of Sema3, 
which is centered around the conserved cysteine, to the potent competitive 
inhibition of Nrp-1 binding. To test for the effect of Sema3 C-terminal basic 
domain dimerization in competitive Nrp-1 binding, a heterodimeric peptide, C-
furSemaHet, composed of one subunit of C-furSema and one subunit with only 
the 13 N-terminal helical residues (Figure 5.10) was generated. This peptide 
contains the N-terminal helix with only a single C-terminal arginine. Strikingly, C-
furSemaHet showed potent inhibition of VEGF-stimulated VEGFR-2 
phosphorylation in endothelial cells with near equal potency as C-furSema in situ 
(Figure 5.11B). It was shown that C-furSemaHet also significantly blocks the 
binding of VEGF to Nrp-1 (IC50 = 35 ± 3 nM) in vitro; whereas C-furSemaMon 
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showed much less potency (IC50 = 1.3 ± 0.7 µM) than either C-furSema (IC50 = 
24 ± 1 nM) or C-furSemaHet, emphasizing the importance of the C-terminal 
arginine for competitive Nrp-1 binding. Taken together, these data demonstrate 
that both the N-terminal helical region and a heterobivalent mechanism 
combining a C-terminal arginine contribute significantly to the competitive 
inhibition of binding of VEGF to Nrp-1.  
Discussion 
 Our in situ data demonstrate that a helical region near upstream of the C-
terminal arginine is essential for the high potency of Sema3F in Nrp-1 binding 
and its antagonism of VEGF binding to Nrp-1 as well as VEGF-induced VEGFR-
2 phosphorylation. These data provide the mechanistic basis for a novel 
heterobivalent competitive binding of C-furSema to Nrp-1 in the cellular context. 
The physical location of the heterobivalent Nrp-1 binding sites on Sema3F 
provides mechanistic insights for inhibitor design. Current peptide and small 
molecule inhibitors designed against the C-terminal arginine binding pocket 
generally possess moderate potency. Our data suggest that targeting both helical 
region and C-terminal arginine may achieve higher potency. Indeed, it was 
shown that through covalent tethering of the two Nrp-1 binding sites, they got a 
two order-of-magnitude increase in VEGF antagonizing potency.  
 Besides the important C-terminal region, Sema3 engagement of Nrp-1 is 
more complex with the N-terminal Sema domain of Sema3 binding to Nrp-1 a1 
domain [208]. How the a1 and b1 domains specifically and coordinately 
contribute to the binding potency and specificity between Nrp-1 and Sema3 




Figure 5.10 Schematic representation of the sequence and predicted secondary 
structure of C-furSema, C-furSemaMon, ∆N-C-furSema and C-furSemaHet. C-
furSema corresponds to the full basic domain of Sema3F on the C-terminus. C-
furSemaMon represents the monomeric form of C-furSema which is produced by 
mutating the conserved cysteine to serine to remove the disulfide bond. ∆N-C-
furSema is a protein with deletion in the conserved N-terminal helix region but 
retained the conserved cysteine residue to form dimers. C-furSemaHet is a 
heterodimer with one subunit of C-furSema and one subunit containing 13 N-








Figure 5.11 The N-terminal helical region determines the potent inhibition of 
VEGF binding to Nrp-1 by Sema3F. C-furSema (A) and C-furSemaHet (B) 
equivalently inhibit VEGF stimulated autophosphorylation of VEGFR-2 in PAE 





CHAPTER SIX Conclusions and future directions 
Conclusions 
 Nrp-1 functions as a critical cell surface receptor in the physiological and 
pathological control of cellular motility and migration. Initially, Nrp-1 was 
described as an adhesive receptor in the nervous system and has been 
additionally shown to possess critical roles in the cardiovascular, immune system 
and beyond. Nrp-1 serves as a pleiotropic co-receptor in those processes by 
binding to multiple ligands and facilitating molecular cross-talk between different 
Nrp-1-dependent ligand families-stimulated signaling pathways. Our data 
suggest the nature and physical basis for the observed high binding of VEGF and 
Sema3F to Nrp-1 and provide the molecular mechanism for the reported trans-
cellular adhesion between Nrp-1 and integrins in pathological context.  
Understanding the nature of Nrp-1 activation by ligands and receptor 
coupling is critical for understanding its pleiotropic function. Initially, Nrp-1 was 
reported to function as a versatile co-receptor in cellular signaling through 
physically engagement with VEGFR-2 and other adhesive and signaling 
receptors in cis. This coupling mode, in theory, is able to coordinate both 
extracellular and intracellular association. In the engagement of Nrp-1 with 
VEGFR-2, ligand-induced extracellular holocomplex formation and GIPC-bridged 
intracellular association are both required for VEGFR-2 internalization, recycling 
and signaling in arteriogenesis [86]. However, GIPC-bridged Nrp/integrin 
association was thought to be fully responsible for their physical and functional 
integration. Until recently, Nrp-1 was shown to enhance α5β1-mediated cellular 
adhesion on fibronectin independent of its intracellular domain [89] and a 
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pathological role has been demonstrated for the trans-cellular adhesion between 
Nrp and integrin [78], indicating the importance of the ECD in Nrp/integrin cellular 
coupling. Indeed, our data in chapter three and four demonstrate that ECD-
mediate physical association occurs in an integrin activation-dependent manner 
between Nrp-1 extracellular b1b2 domains and α5β1 integrin, explaining the 
reported decrease in tumor cell adhesion and trans-migration across endothelial 
cells when Nrp knockdown and anti-α5 antibody were applied. Integrin ligand 
fibronectin promotes this interaction. Moreover, Nrp-1 directly interacts with 
fibronectin through its b1 domain. The mutual binary interactions within 
fibronectin/Nrp-1/α5β1 integrin complex provide a foundation for the bridging 
mechanism of fibronectin, thus explaining the enhancing effect of fibronectin to 
the direct physical interaction. Our data suggests that the basement ECM 
component fibronectin may help to stabilize the Nrp-1/integrin complex formation, 
which in turn stabilizes endothelial cell attachment to provisional ECM during 
angiogenesis. This pathological trans-Nrp-1/α5β1 integrin interaction can be 
generalized to platelet physiology. Similarly, our data suggests an integrin 
activation-dependent interaction between Nrp-1 and αIIbβ3 integrin. This 
interaction is also mediated by Nrp-1 b1b2 domains and can support CHO cell 
and platelet adhesion to immobilized Nrp-1 ECD. Meanwhile, VEGF-bound 
complex of Nrp-1 is able to enhance ADP-induced and αIIbβ3-driven platelet 
aggregation. In summary, we identified the specific Nrp-1/integrin interactions 
and have extended this work to demonstrate the functional importance and 
contribution of the interactions to integrin-mediated cell adhesion on fibronectin in 
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angiogenesis and platelet physiology during wound healing and provide a 
molecular basis for the integration of Nrp/integrin in cell migration, adhesion to 
ECM, breast cancer initiation and breast cancer stem cell fate determination.  
The specific Nrp-1-ligand interactions control signal initiation and 
transduction and are key to understanding the versatile physiological function of 
Nrp-1. Our data in chapter five provides the molecular basis for the observed 
high affinity binding of VEGF and Sema3F to Nrp-1. Close examination of the 
crystal structure of VEGF HBD in complex with Nrp-1 b1 domain and sequence 
alignment of either Nrp b1 domains or VEGF HBD across vertebrate species 
identified intermolecular interfacing residues and conserved potential contributing 
residues. With mutagenesis of those residues, our data define the specific 
contribution of D160 residue of VEGF. D160 neither localizes in the 
intermolecular interface nor directly form salt bridges with Nrp-1 residues. But 
instead, D160 localizes in close proximity to the intermolecular interface, 
approaching the interacting uncharged residues in the L1 loop of the Nrp-1 b1 
domain. However, sequence alignment demonstrates a charge inclusion in this 
area of Nrp-2 b1 domain, which share overall similar architecture with Nrp-1. The 
sequence diversity in three-dimensional space allows us to interpret our 
biochemical data that in isolation, D160 of VEGF is not the main residue 
contributing to Nrp-1 binding, but negatively regulating Nrp-2 binding via 
electrostatic repulsion with the charged residues in the L1 loop of the Nrp-2 b1 
domain. Nrp-1 is an obligatory co-receptor for VEGF/VEGFR-2 mediated 
angiogenesis. Defining the molecular basis of VEGF and Nrp-1 interaction will 
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provide a picture of how Nrp-1 can specifically bind to and assemble multiple 
molecules into signaling complex. Our work in chapter five also provides the 
molecular basis for high-affinity binding of Sema3F to Nrp-1 through using the 
furin-processed C-terminal domain and demonstrates that the unique 
heterobivalent engagement of Nrp-1 is essential for the high-affinity Sema3F 
binding. The engagement competitively antagonized VEGF binding to Nrp-1 and 
VEGF-induced cellular activation. Our data provide a physical basis for the 
competitive Nrp-1 binding of VEGF and Sema3F and the functional interplay of 
VEGF and Sema3 in diseases associated with angiogenesis. For example, 
abnormal hypervascularization in tumor angiogenesis is associated with VEGF 
upregulation or Sema3 downregulation [209-211].  
In summary, our data defined the molecular basis for cooperative Nrp-1 
binding to multiple extracellular proteins which allows it to function as a central 
physical joint to integrate cellular activation, cell adhesion and directional 
migration (Figure 6.1). Specifically, as to Nrp-1/integrin interaction, based on our 
studies and previous reports, we found that VEGF binds to fibronectin through its 
heparin-II domain [136]. But the binding stoichiometry between VEGF and 
fibronectin is not determined yet. Previous studies suggest an association 
between Nrp-1 and α5 integrin in tumor transmigration across endothelial cells 
during metastasis. Combining the above study and our data, it indicates that Nrp-
1 directly interacts with α integrin subunit. Fibronectin has been shown to interact 
with integrin through two sites: the RGD site and the synergy site [212]. Since 
fibronectin is an antiparallel disulfide bond-linked dimer, the binding stoichiometry 
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between fibronectin and integrin is 2:2. Our data also showed that Nrp-1 directly 
binds to fibronectin through its b1b2 domains. Thus, the binding stoichiometry 
between Nrp-1 and fibronectin is also 2:2. Our data further demonstrated that 
integrin and fibronectin binding sites locate in the distinct regions of Nrp-1 ECD. 
Thus, the binding stoichiometry with the ternary complex of Nrp-
1/integrin/fibronectin is 2:2:2. The crystal structure suggests that VEGF is a 
disulfide-linked dimer. VEGF binding induces Nrp-1 dimerization. Since our data 
suggests that fibronectin functions as a canonical ligand for Nrp-1 and binds to 
the b1 ligand binding pocket, fibronectin and VEGF may competitively bind to the 
same site of Nrp-1 ECD. Thus, the four-molecule complex formation is 
complicated. In one way, fibronectin may compete with VEGF for the binding to 
Nrp-1; in another way, fibronectin can associate with VEGF in the complex 
formation. Whether there is a four-molecule complex formation or whether 
fibronectin and VEGF are mutually exclusive in Nrp-1/integrin complex formation 
has to be determined. The above binding stoichiometry can be applied to both 
cis- and trans-interacting mode (Figure 6.2). Similar to the difference shown for 
Nrp-1 interaction with VEGFR-2, the role of Nrp-1 interaction with integrin may 
also be different between the cis- and trans-mode. While in cis, Nrp-1 facilitates 
integrin internalization and recycling, in trans, Nrp-1 may limit integrin 
internalization, but instead, enhance integrin association with circulating ECM, 
which in turn promotes Nrp-1/integrin interaction and facilitates endothelial 




Nrp-1 serves as a versatile cell surface receptor in physiological and 
pathological context through the cooperative actions of its extracellular, 
transmembrane (TMD) and intracellular domains.  
Our data demonstrate the importance of the extracellular domain in 
receptor coupling and ligand binding. As to the coupling with integrins, our data 
provide a physical context for the important physiological function of Nrp-1 in 
mediating cell adhesion and migration and platelet physiology. In platelet 
physiology, the effect of the trans-Nrp-1/αIIbβ3 integrin in mediating platelet 
adhesion to Nrp-1 protein prompted us to detect whether this physical interaction 
can support endothelial cell/platelet coupling in wound healing. This work will 
extend our understanding of the physiological function of Nrp-1 in cardiovascular 
system in that Nrp-1 not only promotes endothelial cell angiogenesis, but also 
modulate the cellular events before the onset of angiogenesis during wound 
healing through mediating the coupling between endothelial cells and platelets.  
In addition to the important role of Nrp-1 in development and homeostasis, 
aberrant Nrp-1 pathway activation has been observed in diverse tumors, 
including those of the prostate, lung, gastrointestinal tract, numerous additional 
organs and even hematopoietic tumors [213, 214]. Importantly, Nrp-1 expression 
contributes to the invasiveness and metastatic potential of these tumors. For 
example, Nrp-1 functions in an autocrine pathway to promote colon carcinoma 
migration, lymph node metastasis, and tumor cell survival [215]. Based on the 
ubiquitous expression of Nrp-1 and integrin, it is promising to understand whether 
Nrp-1/integrin interactions can support tumor cell/endothelial cell/platelet 
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adhesion in tumor transmigration and spreading during metastasis. 
Comprehensive studies of the physiological and pathological implications of the 
trans-Nrp-1/integrin interaction prompts us to develop antagonists targeting Nrp-
1/integrin coupling instead of targeting ligand binding, which in long-term, may 
cause severe problem in hemostasis, like bleeding [160]. Blockade of Nrp-
1/integrin coupling may provide synergistic benefit, especially in control of 
pathological cell migration and metastasis. Indeed, it was recently reported that 
Nrp-1 inhibition enhanced the anti-adhesive effects of β1 integrin-inhibition in 
carcinoma cells [143], suggesting a synergistic role of targeting Nrp-1/α5β1 
integrin coupling in antagonizing tumor survival, adhesion and migration. Besides 
Nrp-1, Nrp-2 is also highly expressed and has been demonstrated to associate 
with integrins in various tumor types. For example, Nrp-2 interacts with α6β1 
integrin to regulate cytoskeleton connection and focal adhesion formation on 
laminin in breast cancer cells [85]. Moreover, Nrp-2/α6β1 autocrine loop 
contributes to breast cancer initiation [116]. Interestingly, both Nrp-2 and α6β1 
integrin bind to PDZ domain containing protein GIPC [22, 138], leading to the 
hypothesis that Nrp-1, Nrp-2 and α5β1, α6β1 integrins may cross-interact. Thus, 
it will be important to further define the binding generality and specificity between 
Nrps and integrins to facilitate therapeutic development in those tumors.    
In light of functions in cancer metastasis, Nrp-1 knockdown has been 
shown to suppress cancer cell migration in vitro and metastasis in vivo [38]. For 
tumor cells to disseminate, tumor cells undergo the prerequisite event—epithelial 
to mesenchymal transition (EMT) to migrate away from the tumor colonies. Nrp-1 
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has been demonstrated to regulate EMT process in oral squamous cell 
carcinoma (OSCC) [216], indicating a role for Nrp-1 in tumor metastasis initiation. 
The metastatic spreading through blood circulation requires the entry of tumor 
cells through a process called intravasation. It was demonstrated that integrin β1 
expression on tumor cells allows their interactions with endothelial cells and 
facilitates tumor cell transendothelial migration in the process of intravasation. 
The trans-Nrp-1/α5β1 integrin interaction shown by our data may be involved in 
the intravasation process. In the hostile blood circulation, platelets have been 
reported to promote tumor metastatic dissemination through shielding tumor cells 
from shear force and immune response [217, 218], facilitating tumor cell arrest at 
the vessel wall [219] and assisting tumor cell transmigration across endothelial 
cells [220]. Complicated tumor cell-platelet interactions, which are bidirectional 
and reciprocal, play important roles in tumor growth and dissemination. Our data 
suggested trans-Nrp-1/αIIbβ3 integrin interaction maybe involved in tumor cell-
platelet interactions. Nrp has been suggested to associate with α5 integrin to 
enhance Nrp-expressing tumor cell adhesion with endothelial cells, thus 
facilitating tumor cell transmigration across endothelial cells [78]. Our data 
suggests that the trans-Nrp-1/α5β1 integrin interaction underlies Nrp-expressing 
tumor cell and α5 integrin-expressing endothelial cell adhesion. So in summary, 
Nrp-1 is proposed to participate specifically in the process of metastasis, from 
initial EMT, intravasation to blood circulation spreading and extravasation, 
indicating the important pathological implications of ECD-mediated Nrp-1/integrin 
association (Figure 6.3).  
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 As to ligand binding, the primary function of Nrp-1 is recruiting ligands to 
the cell surface through high-affinity interactions to promote receptor coupling 
and signaling activation. Our and others’ data provide the basis for specific Nrp-
1-ligand interactions in either angiogenesis or axon guidance biochemically and 
structurally [93, 200].  
 In VEGF signaling, where the pleiotropic functions of VEGF are mediated 
by the cell surface receptor VEGFR-2 and aided by the mandatory co-receptor 
Nrp-1, Nrp-1 is intimately connected to the ability of endothelial cells to respond 
to ligand concentration gradients leading to directional migration. The 
manipulation of VEGF signaling has demonstrated therapeutic potentials. 
However, the efficacy of the current anti-angiogenic therapies is limited by the 
lack of molecular information regarding the structural organization of the pro-
angiogenic complex, VEGF/ Nrp-1/VEGFR-2. A detailed computational modeling 
of VEGF and its receptors predicts that inhibition of Nrp-VEGFR coupling is more 
effective than blocking ligand binding [221]. Thus detailed molecular 
understanding of VEGF/Nrp-1/VEGFR-2 interactions will provide novel strategies 
for potent inhibition of VEGF-dependent angiogenesis.  
Similarly, Nrp-1 function in the axon growth cone allows directional 
migration in response to Sema3 concentration gradients. In these processes, 
Nrp-1 functions in ligand-dependent control of cellular motility. Molecular insights 
of Nrp-1/Sema3 interactions is of particular importance for understanding Sema3 
functions, since Nrp-1 is obligatory for the diffusible Sema3 binding to cell 
surface [222]. Our data explains in molecular detail about furin-cleaved 
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Sema3F/Nrp-1 interaction and suggests a critical role of the furin-exposed C-
terminal arginine in high-affinity Nrp-1 binding. Despite these data, the 
importance of furin processing in physiological Sema3 signaling has remained an 
open question. The recent report that Kallmann’s syndrome, a serious genetic 
disease resulting from defects in axon guidance, can be caused by mutations in 
furin-cleavage sites in the C-terminal domain of Sema3A [223], argues strongly 
for the physiological importance of furin-processing and Nrp-engagement. The 
mechanistic insights of Nrp/Sema3 interaction will contribute to the 
understanding of the competition between Sema3 and VEGF for Nrp binding and 
the fine-tuning of VEGF mediated angiogenesis by Sema3, including Sema3A, 
3B and 3C, besides Sema3F in cardiovascular system. Studies of the regulation 
and function of distinct furin-processing in Sema3 activity and Nrp-1 engagement 
in neuronal and cardiovascular development are important and needed for the 
future design of Nrp inhibitors.  
The basis for ligand binding has been a source of intensive study and 
fundamental insights regarding the importance of a C-terminal arginine residue 
have proven fruitful [56, 81, 93, 187, 188]. Besides the canonical C-terminal 
arginine-containing ligands, like VEGF and Sema3, a host of potential Nrp-1 
ligand families have been identified and continued work is needed to define the 
physiological role of Nrp-1 signaling by these ligands. For example, our data 
demonstrate an enhancing effect of fibronectin in Nrp-1/α5β1 integrin interaction 
and a direct physical interaction between fibronectin and Nrp-1 b1 domain. It is 
promising to define the generality of Nrp-1/ECM interactions. Physiologically, 
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Nrp-1 has been shown to facilitate primary human endothelial cell adhesion to 
laminin, fibronectin and gelatin [39]. Pathologically, Nrp-2 suppression decreased 
pancreatic cancer cell adhesion to fibronectin, laminin and collagen IV [68]. It will 
be interesting to discover the extent of Nrp/ECM interactions, and whether these 
interactions are coupled to or competitive with binding of canonical signaling 
ligands.  
 Compared to the well-studied Nrp-1 extracellular domain, which serves in 
ligand binding [93], cell adhesion [132] and receptor oligomerization [51, 52], 
structural and functional studies of Nrp-1 transmembrane domain (TMD) are 
further left behind because of its hydrophobicity and lack of stability in isolation. 
One additional function besides membrane anchoring identified by amino acid 
sequence searching and in vitro assay is that Nrp-1 TMD possesses a conserved 
double GxxxG motif, which confers Nrp-1 TMD strong inherent dimerization 
potential [189]. Glycine interactions between GxxxG motifs are important for the 
dimerization of TMD of multiple receptors, including erythrocyte glycophorin A 
(GPA) [224-226], ErbB receptors [227, 228], insulin receptors [229] and αIIb 
integrin. Since Nrp-1 intracellular domain has no intrinsic enzymatic activity, Nrp-
1 requires recruiting various partners in the cell membrane to assemble receptor 
complexes, which are of prime importance for cellular signaling. Future studies 
are needed to investigate how the GxxxG motifs in the TMD of multiple 
receptors, including Nrp-2, PlexinA1 and integrin αIIb, contribute to the hetero-
dimerization or hetero-oligomerization with Nrp-1. Given the versatile functions of 
Nrp-1 in physiological and pathological processes, understanding the TMD 
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interactions may facilitate the design of new reagents to detect the contribution of 
this hydrophobic domain in ligand binding and signal transduction in physiological 
context and promote the development of novel strategy to interfere with Nrp-1 
signaling through preventing TMD coupling.  
 Unlike the lack of functional studies in Nrp-1 TMD, several studies suggest 
the functional implications of Nrp-1 intracellular domain in canonical signaling 
receptor coupling, internalization and recycling. However, the intracellular 
molecules that can form direct interactions or indirectly bridge with Nrp-1 remains 
to be determined. While GIPC is clearly a critical adaptor protein mediating Nrp-
1/VEGFR-2 or α5β1 integrin intracellular coupling, other PDZ domain-containing 
proteins have been suggested and are being pursued in the newly-defined Nrp-1 
functions, e.g., regulation of hedgehog signaling [26]. Meanwhile, although the 
functional significance of GIPC in angiogenesis has been demonstrated, the 
molecular basis for GIPC-dependent assembly of signaling complex, either Nrp-
1/integrins, or Nrp-1/VEGFR-2 is not known yet. Amino acid sequence searching 
identified GIPC-binding motif in the C-terminus of the above receptors. Both α5 
and α6 integrins contain the GIPC binding sequence, serine-aspartic acid-alanine 
(SDA) and serine-tyrosine-serine (SYS), at the C-terminus, respectively. 
However, while rat VEGFR-2 possesses the GIPC binding motif, serine-proline-
valine (SPV), neither human nor mouse VEGFR-2 has, indicating that GIPC-
bridged Nrp-1/VEGFR-2 interactions and their functional integration in 
angiogenesis are species specific. Nrp-1 C-terminal serine-glutamic acid-alanine 
(SEA) motif was shown to bind to GIPC. With the binding motif identified, in vitro 
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binding assay and structural studies using X-ray crystallography and 
complimentary structural techniques are needed to determine the structural basis 
for specific VEGFR-2, integrin and Nrp-1 binding to GIPC. Moreover, mechanistic 
insights into the downstream signaling of GIPC and its structural coupling with 
the downstream molecules are needed to investigate.  
 So in summary, the basis for receptor/ligand and receptor/co-receptor 
coupling remains an important area for future research. In particular, the nature 
of Nrp-1 binding to signaling receptors in both the presence and absence of 
ligand remains unclear. The architecture and differential specific coupling to 
VEGFR family members, plexins, and integrins remains to be determined. These 
insights will be particularly important in understanding additional fundamental 
aspects of Nrp-1 function. Additionally, while current therapeutic strategies focus 
on blocking ligand binding, inhibition of receptor coupling may, in fact, prove 
superior to traditional inhibition strategies [221]. Taking integrin for example, 
since integrins serve as mechanosensors, adhesion molecules and signaling 
transducing platforms in the pathology of many diseases, therapeutics targeting 
integrins are of great interest in disease treatment and prevention. Current 
therapeutic strategies focus on disrupting ligand binding using either antibodies, 
disintegrins and small molecule inhibitors, our data suggests receptor coupling 
targeting represents a distinct but superior mode of action for targeting integrin 
signaling. Disrupting the ligand binding, e.g., the current anti-platelet drug 
targeting fibrinogen/αIIbβ3 integrin binding, in long term, would cause severe 
problems in hemostasis, like bleeding. Our data shows that Nrp-1 binds to the 
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distinct sites other than the canonical ligand binding site of integrin, indicating 
that targeting Nrp-1/integrin coupling would not interfere with normal integrin 
ligand binding and in long term, other important aspects of integrin functions. 
Taking VEGF for example, VEGF is one of the most potent angiongeic mitogens. 
Targeting VEGF would prevent tumor angiogenesis, thus blocking tumor growth 
and progression. A humanized monoclonal antibody Avastin, targeting VEGF 
binding to VEGFRs, has been shown to be effective in targeting tumor growth at 
beginning, but for long term, would cause severe side effect and is ineffective in 
long term recurrence. Besides the role in pathological angiogenesis, VEGF also 
regulates many aspects of essential physiological processes, like angiogenesis, 
female reproductive functions and endochondral bone formation and so on [230]. 
Our data suggests that Nrp-1/VEGF signaling may participate in integrin 
mediated functions, like α5β1 integrin mediated cell adhesion and migration, 
αIIbβ3 integrin mediated platelet aggregation. Moreover, VEGF binding stabilizes 
the Nrp-1/integrin complex formation. Thus, targeting Nrp-1/integrin coupling 




















Figure 6.1 Nrp-1 regulates diverse signaling pathways through coordinating the 
cooperative activities of extracellular and intracellular domains. 1) & 2) Nrp-1 
directly interacts with the integrin, either α5β1 or αIIbβ3 ECD, in an integrin 
activation-dependent manner in both cis- and trans-interacting mode and 
mediating trans-cellular adhesion. 2) Nrp-1 b1b2 domains (lined by yellow line) 
are necessary and sufficient for the interaction with integrin ECD (lined by yellow 
line). Nrp-1 b1b2 domains also directly bind to fibronectin, which enhances α5β1 
binding. 3) VEGF binding (through different parts in the ECD) bridges a 
holocomplex formation between Nrp-1 and VEGFR-2 in both cis- and trans-
interacting mode. The two receptors may directly interact in the ECDs in a ligand-
independent manner. 4) Nrp-1 modulates and specifies intracellular trafficking of 
signaling complex, including VEGFR-2 and integrins. 5) Binding of the adaptor 
protein, GIPC, allows coupling of ligand binding to signaling events mediated by 






Figure 6.2 Ligand mediated four molecule-interactions within Nrp-1 and integrin 
complex in both cis- and trans-interacting mode. 1) VEGF has been 
demonstrated to specifically bind to fibronectin to affect integrin/growth factor 
receptor signaling crosstalk and cellular responses. 2) Our data indicates the 
direct interaction between fibronectin and Nrp-1 extracellular b1b2 domains. 
However, the binding stoichiometry is unknown yet. 3) VEGF directly binds to 
Nrp-1 b1 ligand binding pocket through its C-terminal R. 4) Our data shows the 
specific association between Nrp-1 b1b2 domains and integrin ECD, including 
α5β1 and αIIbβ3 integrin, in cis-interacting mode. 5) In trans-interacting mode, 
Nrp-1 b1b2 domains can also interact with integrin ECD to promote integrin effect 

















Figure 6.3 Specific involvement of Nrp-1 in cancer metastasis. Nrp-1 was shown 
to induce and maintain tumor cell epithelial-to-mesenchymal transition (EMT), 
which is a prerequisite event to induce tumor metastasis. Nrp-1 was also 
demonstrated to mediate cancer cell migration and invasion across the basement 
membrane, which is followed by intravasation across endothelial cells to enter 
the blood circulation. In the hostile blood circulation, platelets interact with tumor 
cells through the specific cell surface receptor interactions. The trans-Nrp-
1/αIIbβ3 integrin interaction may be involved in. The trans-Nrp-1/α5β1 integrin 
interaction may also participate in tumor extravasation. Moreover, functional 





AP: alkaline phosphatase 
BSA: bovine serum albumin 
CHO: Chinese Hamster Ovary 
EMT: epithelial to mesenchymal transition 
ECM: Extracellular matrix 
GAG: Glycosaminoglycan 
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